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Abstract 
Binding Properties of Large Antiviral Polyamides (PA1 and PA25) and  
Natural Product Derivatives as Inhibitors of Serine Hydrolases 
 
(June 2014) 
 
Elena Vasilieva, M.S., University of Missouri, St. Louis, MO, USA. 
 
Chair of Committee: Dr. C. M. Dupureur 
 
Polyamides (PAs) are a class of DNA minor groove binders that were developed 
from the natural product Distamycin A. PA25 (20-ring PA) showed better activity (3-
fold) in the elimination of HPV16 episomes than PA1 (14-ring PA). Binding studies of 
PA1 and PA25 were performed in the long control region of HPV16 (7348-122 bp). PA1 
showed similar binding affinity to perfect match and single mismatch binding sites. PA1 
bound to double, triple, and quadruple mismatch sites with lower affinity in comparison 
with binding affinities of perfect match and single mismatch binding sites. PA25 bound 
with similar binding affinity to perfect through triple mismatch binding sites. PA25 
bound quadruple mismatch sites and in the manner that does not follow PA binding rules 
developed by Dr. Dervan’s group. Therefore, it was concluded that PA25 is better at 
accommodating mismatches in its binding sites.    
The serine hydrolase family has a catalytic triad that consists of Serine, Histidine, 
and Glutamic/Aspartic Acid. Acetylcholinesterase (AChE) belongs to the serine 
hydrolase family. AChE hydrolyzes acetylcholine to stop signal transmission between 
iii 
 
neurons and thus is a drug target for Alzheimer’s disease. The previously extracted 
natural product cyclophostin showed a low nM inhibitory effect against AChE; its 
phosphonate derivative irreversibly modified the AChE active site. The cyclophostin 
phosphate or phosphonate, bicyclic or monocyclic derivatives showed low μM potency 
against human AChE. Fluorination of the monocyclic phosphonate cyclophostin showed 
no inhibitory effect against AChE up to 100 μM.  
 Hormone sensitive lipase (HSL) is also a serine hydrolase. It hydrolyzes 
diacylglycerol to monoacylglycerol and is a drug target for type II diabetes. The 
previously extracted natural product cyclipostin, showed low nM potency against HSL. 
Cyclipostin has a similar structure to cyclophostin; the only difference is that cyclipostin 
has a long alkyl chain off the phosphate moiety. SAR studies on the cyclipostin 
derivatives showed that absence of the long alkyl chain and the phosphate to phosphonate 
substitution in the bicyclic framework decreased the inhibitory effect against HSL while 
lactone ring opening did not affect inhibition. SAR studies in the monocyclic 
phosphonate framework showed that compounds with the alkyl chain on the phosphate 
moiety have a better inhibitory effect than compounds with the alkyl chain on the 5
th
 
carbon in the seven-membered ring.  
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CHAPTER I 
POLYAMIDE BINDING PROPERTIES  
IN THE MINOR GROOVE OF DNA. 
1.1 Background: 
The information required for the life of the cell is encoded in the DNA 
macromolecule.  DNA consists of two anti-parallel polydeoxyribonucleotide strands 
twisted around each other (Dickerson et al., 1982).  DNA strands include four different 
nucleotides: adenine (A), thymine (T), guanine (G), and cytosine (C) (Saenger, 1984). 
The two strands are held together by hydrogen bonds between different base pairs that are 
paired with a certain specificity: adenine pairs with thymine and guanine pairs with 
cytosine.  DNA can be structured in B, A, or Z forms (Wing et al., 1980).  Genetic 
information is generally stored in B-form DNA molecules.  B-form DNA is characterized 
by basepairs being perpendicular to the vertical axis of the helix and each turn of the 
helix containing ten base pairs (Wing et al., 1980).  B-form DNA has a wide (12 Å) and 
shallow major groove and a narrow (4-6 Å) and deep minor groove.  Each of the 
nucleotides displays a unique surface at the major and minor grooves (Fig. 1.1) (Saenger, 
1984).  
Certain DNA binding proteins bind to biologically relevant DNA fragments using 
hydrogen bonds, electrostatic interactions, and van der Waals interactions (Pabo & Sauer, 
1992). Therefore, the specific arrangement of chemical features on the DNA minor and 
major grooves can be “read” by DNA binding proteins. 
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Figure 1.1: The Structure of DNA. (A) X- ray crystal structure of B-form DNA. The 
phosphodiester-linked deoxyribose backbone is presented in blue, and the Watson-Crick 
base pairs are presented in gray (PDB 1 YSA) (Farkas, 2010). (B) Minor groove patters 
of Watson-Crick base pairs. Circles with dots represent the lone pairs (hydrogen bond 
acceptors) of N3 in G and A or O2 in C and T. A circle with an ‘H’ inside represents 
hydrogen from NH2 of G (hydrogen bond donor) (Dervan & Edelson, 2003). Adapted 
from (Farkas, 2010). 
 
Major Groove 
Major Groove 
Minor Groove 
Minor Groove 
 2  3  2 
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1.2 Minor Groove DNA Recognition by Natural Products: 
 The minor groove binding polyamides were developed from the parent natural 
products Distamycin A and Netropsin (Fig. 1.2) (Arcamone et al., 1964; Zimmer & 
Wahnert, 1986). Both of those compounds are antibiotics consisting of repeating pyrrole 
units with amide bonds connecting them. They have a natural curvature that conforms to 
the minor groove of B-form DNA (Tse & Boger, 2004). Distamycin A binds five 
consecutive A∙T base pairs while Netropsin binds four consecutive A∙T base pairs 
(Melander et al., 2004).  The depth of the minor groove is dependent on the DNA 
sequence: it will be deeper if the sequence consists only of A and T; it is shallower if has 
guanine and cytosine. This is due to the protruding amine of guanine into minor groove 
of the DNA (Nelson et al., 2007). DNA can accommodate one or two anti-parallel 
molecules of Distamycin A depending on its sequence. If the DNA sequence contains 
five consecutive A∙T base pairs, then it can accommodate only one molecule of 
Distamycin A, but if it contains four A∙T base pairs or any G∙C base pairs, the DNA will 
accommodate two anti-parallel Distamycin A molecules in the same binding site (Fig. 
1.3) (Nelson et al., 2007). The Netropsin molecules cannot form anti-parallel or head-to-
head dimers in the minor groove due to electrostatic repulsion (Lah & Vesnaver, 2004). 
These natural products are problematic as drugs because: i) they are cytotoxic 
towards cells; and ii) they are specific only for A∙T base pairs and therefore do not have 
enough DNA sequence specificity for use in therapy (Bialer et al., 1979). 
1.3 Evolution of Polyamide Recognition of the DNA Minor Groove: 
 To address the issue of poor specificity with Netropsin, it was suggested to 
replace an individual N-methylpyrrole (Py) with N-methylimidazole (Im) (Fig. 1.4)  
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Figure 1.2: Chemical Structure of Distamycin A and Netropsin. Distamycin A and 
Netropsin bind to AT rich sequences in the minor groove of DNA (Nelson et al., 2007). 
Distamycin A binds in 1:1 and 2:1 Distamycin A:DNA ratios. Netropsin binds only in a 
1:1 Netropsin:DNA ratio.  
 
 
 
 
 
 
Distamycin A 
Netropsin 
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Figure 1.3: X-ray Structure of Distamycin A Bound in the Minor Groove of DNA. 
(A) 1:1 Distamycin A:DNA complex (PDB 2DND) (Coll et al., 1987). (B) 2:1 
Distamycin A:DNA complex (PDB 378D) (Mitra et al., 1999). Adapted from (Farkas, 
2010). 
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Figure 1.4: The Most Common Polyamide Building Blocks. Amino acids based on  
N-Methylpyrrole (Py), N-Methylimidazole (Im), γ-aminobutyric acid (γ-turn), and β-
alanine (β or β-Ala).  
 
 
 
 
 
 
 
 
 
 
 
N-Methylpyrrole N-Methylimidazole 
γ-aminobutyric acid 
 
 
β-alanine 
 
α 
α 
β 
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(Dervan, 1986) (Kopka et al., 1985). The first time the Im building block was introduced, 
the predicted site (G(A/T)(A/T)) was designed with a 1:1 binding model in mind; 
however the sequence that was recognized by the ImPyPy polyamide was G(A/T)C. 
After additional experiments (affinity cleavage), it was recognized that the polyamide 
ImPyPy binds in a 2:1 polyamide:DNA binding mode with an antiparallel preference 
(Fig. 1.5) (Wade, 1992). NMR experiments with the ImPyPy ligand bound to                
5’-wGWCw-3’ (where W is A or T) confirmed a 2:1 binding model of polyamide:DNA 
(Mrksich et al., 1992). The polyamides (ImPyPy) were bound antiparallel to each other: 
each polyamide molecule “read” one strand of DNA with the N-terminus of polyamide 
aligned with the 5’ end of the DNA strand and the C-terminus aligned with the 3’ end of 
the DNA strand. These results lead to two conclusions: an Im/Py pair recognizes a G∙C 
pair, Py/Py recognizes an A∙T or T∙A base pair, and Py/Im recognizes a C∙G base pair 
(Fig. 1.6).   
1.3.1 Hairpin Polyamides: 
 To increase binding affinity, specificity, and the range of targeted DNA 
sequences, a second generation of polyamides was created in which two linear polyamide 
molecules where linked together. This was first attempted by linking two 3-ring 
polyamides in the middle, creating a homodimer (H-pin) that bound specifically to the 
5’-wGWCw-3’ DNA sequence (Fig. 1.7 A). The linking of the two polyamides improved 
binding affinity 10-fold; the length of the linker had little influence on binding affinity 
(Mrksich, 1993). The first heterodimer polyamide was created by linking the ImPyPy 
polyamide with Distamycin A. The binding affinity of linked polyamides increased at 
least 7-fold over their parent linear polyamides (Mrksich, 1994b).  
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Figure 1.5: 1:1 and 2:1 Binding Models for the Complexes Formed between the 
Polyamide (ImPyPy) and DNA. (A) 1:1 complex of ImPyPy with the DNA sequence 
5’-G,C(A,T)3-3’. (B) 2:1 complex of ImPyPy with the DNA sequence 5’-TGTCA-3’. 
The circles with dots inside represent lone electron pairs (hydrogen bond acceptors) from 
N or O2 of A, T, G, C. The circle with the H inside represents the hydrogen atom from 
the NH2 of the G (hydrogen bond donor). Dashed lines represent possible hydrogen bonds 
(Wade, 1992). 
  
 
 
 
 
  
 
 
 
A B 
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Figure 1.6: Schematic of a Py-Hp-Py-Py-γ-Im-Hp-Py-Py-Py-β-Dp Hairpin       
Polyamide-DNA Complex. Hp represents hydroxypyrrole. R group represents β-Dp  
(N,N-dimethylaminopropylamine). The solid curved lines represent phosphate backbone 
of each DNA strand. Adapted from (Dervan & Edelson, 2003). 
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Figure 1.7: Examples of PA Structure. (A) Polyamide heterodimer linked covalently 
through the nitrogens of the central pyrrole rings with a butyl linker (H-pin) (Mrksich, 
1994b). (B) Model for the complex made between the hairpin polyamide and 5’-ATTGT-
3’ DNA sequence. Circles with dots represent lone pairs of N3 of A and G, and O2 of C 
and T. Circles containing the letter H represent the N2 hydrogen of G. Possible hydrogen 
bonds are shown by dotted lines (Mrksich, 1994a; Mrksich, 1994b).   
 
 
 
 
 
 
 
 
A B 
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Because linking two polyamides in the middle was synthetically challenging, a 
linker was introduced that connected the N-terminus of one polyamide strand to             
C-terminus of another polyamide strand to form a heterodimer hairpin polyamide (Fig. 
1.7 B). Glycine, β-Ala, γ-aminobutyric acid (GABA) and 5-aminovaleric acid were 
compared for the function of a linker between two 3-ring polyamides (Mrksich, 1994a). 
Hairpin polyamides containing γ-aminobutyric acid (Fig. 1.4) showed the highest binding 
affinity and specificity for DNA when compared to those containing the other three 
linkers and 300-fold greater binding affinity than unlinked polyamides. According to 
NMR studies, the linker (turn) between the two polyamide strands is inserted deep into 
the minor groove, locking the register of the units pairing and preventing the polyamide 
strands from sliding with respect to the DNA (Lamamie de Clairac, 1997). GABA as a 
turn in the 6-ring hairpin polyamide has a 100-fold  greater affinity and specificity for 
A/T over G/C, due to the steric clash with the exocyclic amine of guanine (Mrksich, 
1994a).  
The specificity of γ-aminobutyric acid as a turn in the 6-ring hairpin polyamide is 
30-fold greater towards A/T than C, while there is no tolerance at all towards the G 
nucleotide (Swalley, 1999). The flanking nucleotide to the γ-aminobutyric acid, which is 
featured as a turn in the 6-ring hairpin polyamide, has only a 3-fold discrimination 
between A/T and G/C nucleotides (Geierstanger et al., 1996). The hairpin polyamides 
with γ-aminobutyric acid as a turn showed 100-fold greater affinity over H-pin 
polyamides (Greenberg, 1998).  
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1.3.2 DNA Binding Affinity with Increasing Polyamide Size:   
Longer PAs bind longer sequences, and are therefore more specific, up to a point. 
A 6-ring hairpin polyamide showed a 3.7x10
10
 (M
-1
)
 
association constant while an 8-ring 
polyamide showed a 1.2x10
10
 (M
-1
) association constant meaning that the longer 
polyamide had a 3-fold lower affinity (Trauger et al., 1996b; Turner, 1997). This 
phenomenon was due to the polyamide being more curved compared to the DNA helix. 
Any polyamide longer than five contiguous rings experienced lower ligand affinity and 
decreased specificity (Kelly et al., 1996; Lamamie de Clairac, 1999). The more Im 
residues that were placed in the polyamide, the more curved the polyamide became (Fig. 
1.8) (Han et al., 2012).  
1.3.2.1 Introduction of β-Alanine: 
To address the curvature problem, β-Ala was introduced as a flexible linker in the 
middle of such linear polyamides (Fig. 1.4) (Geierstanger et al., 1996; Trauger et al., 
1996a; Lamamie de Clairac, 1999). This flexible linker provided relief for H-bond 
registry for register mismatches, allowing all subunits to make hydrogen bonds 
appropriately.   
 β-Ala displays recognition behavior similar to that of the pyrrole ring with           
β-Ala/β-Ala, β-Ala/Py, and Py/β-Ala all recognizing T∙A or A∙T base pairs while Im/β 
recognizes the G∙C base pair and β/Im recognizes the C∙G base pair (Turner, 1998). β-Ala 
at the end of the 6-ring helix polyamide has a 300-fold specificity towards T and A 
nucleotides over G and C nucleotides (Swalley, 1999).   
First, Table 1.1 summarizes examples where PAs with a β-Ala unit bind more 
tightly than PAs with a pyrrole unit (Table 1.1 Cases #1-5). Second, the PAs show better  
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Figure 1.8: Structure of the Four-Ring PA Calculated by Density Functional 
Theory. Indicated angles are the dihedral angles between each Py or Im and the 
contiguous amide (N1-C2-CO-O). The dotted line represents the N-to-N distance 
between the C and N end of polyamide. (A) PyPyPyPy, (B) ImPyPyPy, (C) PyPyImPy, 
(D) ImPyImPy, (E) ImImImIm. Adapted from (Han et al., 2012). 
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Table 1.1: Summary of the Effect of Py Substitution to β-Ala in Polyamides. 
a,c,i,j
(Turner, 1998); 
b
(Bando, 2008); 
d
(Minoshima et al., 2008); 
e
(Han et al., 2013); 
f
(Zhang et al., 2012); 
g
(Wang et al., 2012); 
h
(Bashkin et al., 2013). In the cartoon 
representation of a hairpin polyamide, open circles represent pyrrole, closed circles 
represent imidazole, grey ovals represent indole, β represents β-Ala, and half circles 
Case 
# 
Polyamide # of 
rings 
Target 
Sequence  
(w/o Dp) 
Binding 
Affinity 
Ka (M
-1
) 
Binding 
Affinity 
Specificity 
 
1
a  12 
 
WGWWWWCW 
 
2.5x10
9
 β>Py 
48-fold 
β>Py 
9-fold 
 
1.2x10
11
 
2
b  10 
 
WGCWCC 
 
~5.0x10
5 
β>Py 
20-fold 
N.D. 
 
~1.0x10
7
 
 
3
c 
 
 12 
 
WGWWCWCW 
 
5x10
9 
β>Py 
5-fold 
β>Py 
10-fold 
 
2.4x10
10
 
 
4
d 
 
 8 WCGCGW 
9.1x10
5
 β>Py 
65-fold 
 
N.D. 
 
5.9x10
7 
5
e  10 
 
WGCGCW 
 
3.7x10
6 
β>Py 
621-fold 
Py>β 
9-fold 
 
2.3x10
9
 
6
f  8 
 
WGCWCW 
 
2.5x10
8 
Py>β 
6.5-fold 
N.D. 
 
3.8x10
7
 
7
g 
 
8 
 
WWGCCW 
 
3.7x10
9
 
Py>β 
3-132-
fold  
N.D. 
 
1.2x10
8
 
 
2.8x10
7 
 
8
h 
 
 WWGGCW 
9.1x10
7 
Py>β 
11-fold 
 
8.3x10
6 
9
i  12 WGWWWWCW 
1.2x10
11
 Align.> 
Stag. 
4-fold 
Align.> 
Stag. 
11-fold 
 
2.7x10
10 
10
j  12 WGWWWWCW 
1.2x10
11
 2β>4β 
≥1200-
fold 
N.D. 
 
≤1x108 
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represent γ-turn. N.D. - Not Determined. Align. - Aligned, Stag.  - Staggered. All of the 
units were counted as a ring besides the γ-turn and β-Ala-Dp                                                
(N,N-dimethylaminopropylamine) unit (Case #9 two aligned β-Ala units were counted). 
The sequence was determined for all of the units besides Dp unit. Case #5 Py>β is bold 
emphasize that the specificity is better when PA contains a pyrrole unit between two 
imidazole units, while binding affinity is better when PA contains β-Ala at the same 
location. 
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binding affinity with Py than β-Ala unit are discussed (Table 1.1 Cases #6-8). Finally, 
miscellaneous cases of β-Ala unit met in the literature are discussed (Table 1.1 Cases 
#9,10). 
The first extensive study on the effect of the pyrrole replacement with β-Ala on 
binding affinity to DNA and binding specificity was first performed in 1998 in the lab of 
Dr. Dervan (Turner, 1998).  If the polyamide is longer than four consecutive rings, a       
β-Ala is needed for flexibility, better binding affinity, and better specificity of the hairpin 
(Turner, 1998; Hsu et al., 2007; Bando, 2008). The 12-ring hairpin polyamide 
(ImPyβPyPyPyγImPyPyβPyPyβDp) with two β-Ala on top of each other instead of 2 Py 
showed a 50-fold increase in binding affinity and a 9-fold increase in specificity (Table 
1.1 Case #1) (Turner, 1998). In the case of the 10-ring polyamide 
(AcImImβImPyγImPyPyIndole), the insertion of one β-Ala showed about a 20-fold 
increase in binding affinity over the analogous polyamide with no β-Ala (Table 1.1 Case 
#2) (Bando, 2008).  
It is very important for binding specificity that β-Ala be inserted between two 
imidazole units for GWG or GCG sequence recognition in long polyamides with 
recognition sequences of 8 bp (w/o Dp) (12-ring PA) (Table 1.1 Case #3) (Turner, 
1998). In the case of 12-ring PA (WGWWCWCW), insertion of β-Ala between two Im 
increased binding affinity 5-fold, and specificity increased over 10-fold (Table 1.1 Case 
#3) (Turner, 1998). In the case of 8-ring PA targeting 5’-GCGC-3’, binding affinities 
increase 65-fold and 621-fold upon substituting pyrrole with β-Ala (Table 1.1 Cases #4, 
#5) (Minoshima et al., 2008; Han et al., 2013). However, sequence specificity decreased 
between 9-fold (Table 1.1 Case #5) (Minoshima et al., 2008; Han et al., 2013). For the 
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sequence 5’-TGCGCA-3’, β-Ala is needed as a spring between two imidazole rings to 
reset the register for hydrogen bonds between Im and DNA (G nucleotide).  
More recently, examples of β-Ala unit substitution have resulted in a decrease in 
binding affinity. The target sequence in Zhang et al., 2012 was 5’-WGWGCW-3’ (8-ring 
PA), and the insertion of 2 β-Ala across from one another decreased the binding affinity 
by 7-fold (Table 1.1 Case #6). The same binding affinity decrease upon β-Ala 
incorporation in a 8-ring polyamide has also been recently reported (Wang et al., 2012) 
(Bashkin et al., 2013). Depending on the position of the substitution of Py by β-Ala, the 
binding affinity decreased between 3-fold, 11-fold, and 130-fold (Table 1.1 Cases #7, 
#8).  
Depending on the sequence of the target DNA and the position of β-Ala, binding 
affinities and specificities vary. In the case of another 12-ring polyamide, two β-Ala 
across from one another exhibited better binding affinity and specificity than staggered  
β-Ala by 4.4-fold and 11-fold, respectively (Table 1.1 Case #9) (Turner, 1998).  The 
incorporation of the 2 adjacent β-Ala pairs (4 β-Alanines in total) in the 12-ring 
polyamide was detrimental for binding affinity (≥1200-fold) (Table 1.1 Case #10) 
(Turner, 1998).     
Thus, it appears that an insertion of the β-Ala in 10- to 12-ring PAs improves the 
binding affinity due to relaxing the curvature of the PA to fit the DNA curvature and due 
to alignment of the hydrogen bonds between PA and minor groove of DNA. If a 
polyamide contains eight rings and the target sequence is 5’-GCGC-3’ (Im-Py-Im-Py for 
GCGC) (Turner, 1998; Bando, 2008; Minoshima et al., 2008), then β-Ala is required to 
reset the register of hydrogen bonds between the PA and DNA. In the cases of 8-ring PAs 
18 
 
that target any sequence other than 5’-GCGC-3’, a β-Ala insertion will decrease the 
binding affinity of such a polyamide (Wang et al., 2012; Zhang et al., 2012; Bashkin et 
al., 2013). The insertion of 4β-Ala units nearby each other can also decrease binding 
affinity.  
1.3.3 Recognition of A vs. T by Hairpin Polyamides:  
One of the objectives of polyamide design was to distinguish the recognition of 
the T∙A base pair from the A∙T base pair in minor groove. The hydrogen donor-acceptor 
landscape of the T∙A vs. the A∙T base pair is similar - one hydrogen acceptor on an 
adenine nucleotide and one hydrogen acceptor on a thymine. The differences that were 
used to distinguish them are that the O2 of a thymine protrudes with two lone pairs into 
the minor groove of DNA relative to the nitrogen, with one lone pair, from an adenine, 
giving rise to asymmetric cleft between the O2 of thymine and the C2 of adenine (Fig. 
1.1) (Kielkopf et al., 1998). 
 To distinguish these differences, N-methyl-3-hydroxypyrrole (Hp) was 
synthesized (Fig. 1.6). Hp/Py preferably binds to T∙A over A∙T (Kielkopf et al., 2000). 
Hp containing polyamides had lower binding affinity than polyamides containing Py 
units because of the energetic penalty of hydroxyl group desolvation upon insertion into 
the minor groove of DNA (Wellenzohn et al., 2003). Not long after the development of 
the Hp unit, it was shown that Hp-containing polyamides degrade over time (Marques, 
2002). The solution to this problem was to synthesize hydroxybenzimidazole (Hz) to 
perform the same recognition preference of T∙A over A∙T (Table 1.2) (Renneberg & 
Dervan, 2003). Because the π-conjugation of the Hz unit limits conformational flexibility, 
the pyrrole ring appears slightly over-curved with respect to the DNA helix, leading to  
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Table 1.2: Features of Polyamide that Distinguish between T and A. 
a
(Renneberg & Dervan, 2003); 
b,c
(Zhang et al., 2006b); 
d
(Floreancig, 2000); 
e
(Zhang et 
al., 2012); 
f
(Zhang et al., 2006b). In the cartoon representation of hairpin polyamide open 
circles represent pyrrole, closed circles represent imidazole, β represents β-Alanine, half 
circle and γ is γ-aminobutyric acid. N.A. - Not Applicable. Rings were counted the 
following way: all of the units were counted as a ring besides γ-turn and βDp unit. R vs. S 
column shows which polyamide hairpin enantiomer was studied. Sequence was 
determined accounting for all of the units besides Dp unit. 
Case 
# 
Polyamide # of 
rings 
R 
vs. S 
Target 
Sequence  
(w/o Dp) 
Thymine 
  Ka (M
-1
) 
Adenine 
Ka (M
-1
) 
T/A 
Fold 
 
1
a 
 
  
8 
 
R 
WWXWC 
6.9x10
9 
3.3x10
9 
2 
 
R 4.1x10
8 ≤2.0x107 20.5 
 
R 5.7x10
8
 3.1x10
7
 18.4 
 
2
b 
 
 8 
R  
XGCWCW 
 
3.2x10
8
 7.1x10
7
 4.5 
 
R 6.25x10
8 
2.0x10
8
 3.1 
 
3
c 
 
 8 
S  
XGCWCW 
 
9.1x10
6
 3.6x10
5
 25.3 
 
S 2.6x10
6
 2.9x10
5
 9.0 
 
4
d 
 
 
10 
N.A 
 
 
WWCXGCW 
 
 
1.6x10
10 
1.4x10
10
 1.1 
 
S 4.9x10
9
 6.2x10
8
 7.9 
 
S 1.8x10
8
 1.1x10
8
 1.6 
 
5
e 
 
 
8 
N.A. 
WGCXCW 
3.8x10
7 
3.4x10
7
 1.1 
 
S 2.2x10
7
 2.2x10
6
 10 
 
6
f 
 
 
8 
N.A. 
WGCXCW 
1.1x10
6
 1.1x10
6
 1 
 
S 5.3x10
6
 2.7x10
5
 19.6 
 
N.A. 6.7x10
6
 6.3x10
6
 1.1 
 
S 1.2x10
7
 9.1x10
6
 1.3 
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decreased binding affinity (Table 1.2 Case #1) (Renneberg & Dervan, 2003). For this 
reason, other ways of the distinguishing T from A were explored. 
One way to distinguish T from A in a γ-turn is by substituting the α-position with 
amino or hydroxyl groups. The R enantiomer of an α-amino or α-hydroxyl substitutions 
(OH or NH2) in a γ-turn has just a 4-fold greater preference for T over A in an 8-ring PA 
(Table 1.2 Case #2) (Zhang et al., 2006a). The S enantiomer of an α-amino or α-
hydroxyl substituted γ-turn in 8-ring polyamide has a 9-fold greater preference for T over 
A for an amino substituted γ-turn and a 25-fold preference for T over A for a hydroxyl 
substituted γ-turn (Table 1.2 Case #3) (Zhang et al., 2006a).  The preference of the S 
enantiomer for T over A is a result of an A nucleotide pushing γ-aminobutyric acid out of 
the minor groove.  The S-enantiomer of an α-substituted γ-turn contacting a T nucleotide 
forms a hydrogen bond between the hydroxyl group (amino group) of an α-substituted γ-
turn and the O2 of a T nucleotide.  
For the recognition of T over A in the middle of the binding site by a polyamide, 
any substitutions made in the α position of a β-Ala or any α-substitution of                      
γ-aminobutyric acid show preference for T over A (Table 1.2 Cases #4, #5 and #6) 
(Floreancig, 2000; Zhang et al., 2006b; Zhang et al., 2012). 
The S enantiomer of an α-substituted β-Ala with a hydroxyl group showed the 
best selectivity (8-fold) for T over A when placed between Im and Py units. The S 
enantiomer of an α-amino β-Ala showed little preference between T and A nucleotides 
when placed between Im and Py units (Table 1.2 Case #4) (Floreancig, 2000). If the S 
enantiomer of an α-amino β-Ala is placed between two Im units, then the preference for 
T over A is 10-fold (Table 1.2 Case #5) (Zhang et al., 2012).  
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The S enantiomer of α-hydroxyl-γ-aminobutyric acid in the middle of a 
polyamide between two imidazole units showed the best selectivity (>19-fold) for T over 
A (Table 1.2 Case #6) (Zhang et al., 2006b). The same α-hydroxyl-γ-aminobutyric acid 
between two pyrrole units showed no preference for T over A (Table 1.2 Case #6) 
(Zhang et al., 2006b). The same effect occurred with the α-amino substitution on               
γ-aminobutyric acid in the same polyamide. This preference of γ-aminobutyric acid being 
more selective between two imidazole units is due to the α-substituted groups making 
hydrogen bonds with the N3 of a G nucleotide (Zhang et al., 2006b). 
1.3.4 Hairpin Polyamide Orientation of Binding to DNA helix: 
The forward orientation of PA binding is characterized by the N-terminus 
aligning with the 5’ terminus of the DNA strand and the C- terminus aligning with the 3’ 
terminus of the DNA strand, while reverse orientation of PA binding is characterized by 
the N- terminus aligning with the 3’ end and the C- terminus aligning with the 5’ end. 
The hairpin form of polyamides (6-ring) prefer to bind in a forward orientation over a 
reverse orientation (Fig. 1.9) (Urbach & Dervan, 2001). However, it can be seen from 
extensive studies of hairpin polyamides with β-Ala or a GC rich target sequence that 
hairpin polyamides can prefer a reverse binding orientation over a forward one (White, 
1997; Rucker, 2003). For specificity reasons it is desirable to restrain the polyamide 
binding to one orientation.  
Introduction of the acetylated N-terminal imidazole decreases preference for 
forward binding orientation over reverse to 4-fold, while the polyamide without an acetyl 
has a preference towards forward binding orientation over reverse binding by 16-fold 
(Table 1.3 Case #1) (White S., 1997).  The loss of the preference for the forward  
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Figure 1.9: Hairpin Polyamides can Bind in Forward or Reverse Orientation to the 
Minor Groove of DNA. The forward orientation of hairpin polyamide binding to the 
minor groove of DNA is characterized by the polyamide aligning NC with respect to 
the 5’3’ direction of the DNA strand. The reverse orientation of polyamide binding is 
characterized by the polyamide aligning CN with respect to the 5’3’ direction of the 
DNA strand.  
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Table 1.3: Influence of Substitutions in Hairpin PA on Orientation of PA Binding. 
a
(White, 1997); 
b
(Herman, 1998); 
c
(Tsai et al., 2007); 
d
(Zhang et al., 2006a); 
e
(Rucker, 
2003); 
f
(Meier et al., 2012). In the cartoon representation of hairpin polyamide, open 
circles represent pyrrole, closed circles represent imidazole, β represents β-Ala, B 
represents biotin conjugate, and half circle is γ-turn. N.D. - Not Determined. N.A. - Not 
Applicable. Rings were counted the following way: all of the units were counted as a ring 
besides γ-turn and βDp unit. R vs. S column shows which polyamide hairpin enantiomer 
was studied. Sequence was determined accounting for all of the units besides Dp unit. 
 
 
 
 
 
Case 
# 
Polyamide # of 
rings 
R  
vs.  
S 
Target 
Sequence  
(w/o Dp) 
Bind.Aff. 
Forward 
Ka (M
-1
) 
Bind.Aff. 
Reverse 
Ka (M
-1
) 
Binding 
Fashion 
F/R 
 
1
a 
 
 6 
N.A. 
WWWCW 
1.4x10
7 
8.8x10
5
 16 
 
N.A. 7.6x10
6
 1.9x10
6 
4 
 
2
b 
 
 6 
R 
WWWCW 
3.8x10
9 
<1x10
6 
>3800 
 
S 2.2x10
7 
4.6x10
6 
5 
 
3
c 
 
 8 
R 
WCWCCW 
1.6x10
10
 <1x10
7
 >1600 
 
S 5.8x10
7
 1.2x10
9
 0.05 
 
4
d 
 
 8 
R  
WGCWCW 
 
2.0x10
8 
N.D. Forward 
 
S 2.9x10
5
 N.D. Forward 
 
5
e 
 
 
10 
N.A. 
 
 
WCWWCCW 
 
 
5x10
9 ≤1x107 ≥500 
 
N.A. 
4.1x10
9 
(2 mm.) 
2.0x10
9 
2 
 
6
f 
 
 
8 
N.A.  
 
WCGWC 
 
 
ND because the 
preference was 
determined by melting 
temperature 
experiments. 
Forward 
 
N.A. Reverse 
 
R Forward 
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orientation is attributed to a pyrrole, that is paired opposite to acetylated imidazole, 
rotates 180
o, pushing the tail (β-Ala-Dp) out of the minor groove (Fig. 1.10) (Hawkins, 
2000; Hawkins et al., 2002). 
NMR studies of 6-ring hairpin polyamides with a substitution of β-Ala to glycine 
on the C-terminus of the hairpin shows that this substitution leads to the reverse 
orientation of binding (Hawkins et al., 2002). This phenomenon takes place because of 
the shortening of the tail by one methylene group; the amide carbonyl is pointed into the 
minor groove instead of the amide hydrogen. There are no hydrogen donors for the 
carbonyl to be desolvated; therefore, it is less favorable for glycine to stay along the 
minor groove. Even if the amide hydrogen were pointing into the minor groove, the     
Dp-tail would clash with minor groove; therefore, the last pyrrole is rotated out 180
o
, and 
the tail is pointed out of the minor groove causing the hairpin to lose its preference for the 
forward orientation.  
The preference for the forward binding orientation over reverse for a hairpin 
polyamide can be directed with an α-amino substituted γ-aminobutyric acid (γ-turn). The 
preference of α-amino γ-aminobutyric acid towards forward or reverse orientation 
depends on the enantiomer. The R enantiomer of a 6-ring PA strongly prefers a forward 
orientation of binding (>3800-fold), while the S enantiomer loses preference for forward 
orientation of binding (5-fold) (Table 1.3 Case #2) (Herman, 1998). These preferences 
are observed because, in the forward orientation, the R enantiomer points the α-amino 
group in the minor groove while the S-enantiomer in the forward orientation drives the   
α-amino group into the floor of the minor groove, thereby clashing with it. Therefore, the 
S-enantiomer would rather bind in a reverse orientation where the α-amino group is  
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Figure 1.10: Structure of Hairpin PAs with Acetylated Imidazole and Glycine. (A) 
Structure of Im-Py-Py-γ-y-Py-Py-β-Dp with the C terminal pyrrole, Py6 (red), in the 
normal conformation. The β-Ala in the C terminal allows the Dp tail to follow the 
curvature of the DNA helix (Hawkins, 2000). (B) Structure of AcIm-Py-Py-γ-y-Py-Py-β-
Dp with the C terminal pyrrole, Py6 (red) in the inverted conformation. (C) Structure of 
Im-Py-Py-γ-y-Py-Py-Gly-Dp with C-terminal pyrrole, Py6 (red) in the inverted 
conformation. (D) Structure of AcIm-Py-Py-γ-y-Py-Py-Gly-Dp with C-terminal pyrrole, 
Py6 (red) in the inverted conformation. (B, C, D)There is no contact between polyamide 
tail and minor groove of DNA (Hawkins, 2000; Hawkins et al., 2002). 
A 
C D 
B 
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pointed out of the minor groove of DNA (Herman, 1998). 
The R enantiomer of an α-amino substitution in the γ-turn in an 8-ring hairpin 
polyamide showed a strong preference for the forward orientation and did not bind in the 
reverse orientation, while the S enantiomer of the α-amino substitution showed a 20-fold 
preference for the reverse binding site over the forward one (Table 1.3 Case #3) (Tsai et 
al., 2007). 
An example of the effect of γ-turn substitution can be observed in an 8-ring PA, 
even though imidazole of this PA is acetylated which drives PA to have less preference 
for the forward orientation of binding, the R enantiomer of an α-amino substituted γ-turn 
showed a 690-fold better binding affinity than the S enantiomer for forward orientation 
sites (Table 1.3 Case #4) (Zhang et al., 2006a). 
Substitution of the pyrrole units with 2 β-Ala units across from each other drives 
an 10-ring hairpin polyamide to lose preference between forward and reverse binding 
orientation (500-fold2-fold) (Table 1.3 Case #5) (Rucker, 2003). 
In another case, even the substitution of one pyrrole for β-Ala in the polyamide 
with a β-substituted γ-turn always prefers the reverse orientation of binding based on the 
melting of the PA-DNA complex (Table 1.3 Case #6)(Meier et al., 2012). This problem 
could be resolved by inserting an α-substituted (R) γ-turn, causing the polyamide to 
prefer the forward orientation of binding even though it contains β-Ala. 
In conclusion, the 6- to 10-ring polyamides will lose preference for forward 
binding orientation if the N-terminal imidazole is acetylated, the C terminal β-Ala is 
substituted with glycine, or the S enantiomer of an α-subsituted γ-turn is used. A 6-ring 
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polyamide will gain preference for the forward binding orientation to the DNA helix if 
the R enantiomer of an α-substituted γ-turn is used. 
The substitution on the α-position on γ-aminobutyric acid with an amino group in 
an 8-ring hairpin polyamide does not alter the specificity of the γ-turn; it still prefers 
binding to A and T rather than G and C. However, there is difference in preference of an 
α-amino γ-turn for T over A. For the R enantiomer, this preference for T is about a 3-fold 
difference in binding affinity while for the S enantiomer, it is about an 8.7-fold difference 
in binding affinity (Zhang et al., 2006a). 
1.4 Polyamide’s Effects In Vivo: 
 Polyamide molecules, DNA minor groove binders with easily modified sequence 
targets, have been used as regulators of gene expression. Also, PAs have been used as 
antibacterial, antifungal, and antiviral agents.  
 When a PA molecule binds in the DNA minor groove, the conformation of the 
major groove of DNA is changed (Chenoweth & Dervan, 2009; Chenoweth & Dervan, 
2010). PAs are known to bind with affinities similar to transcription factors (Dervan & 
Edelson, 2003). PAs can access the DNA minor groove even whenever DNA is wrapped 
around the nucleosomes and is not transcribed since PAs accesses the DNA minor groove 
that is on the outside face of the nucleosome. 8-20-ring hairpin PAs penetrate cells easily 
and localize in the cell nucleus. Using these features, PAs have been used to activate, 
deactivate, and recruit many different proteins. Transcription of certain genes has been 
activated by PAs that were linked with artificial activators that further recruited all of the 
important proteins for transcription (Ansari et al., 2001; Burnett et al., 2006). Activation 
of genes by PAs has also been achieved by inhibiting repressor proteins (IE86 for 
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example) (Dickinson et al., 1999). Proteins associated with transcription in HIV (Ets-1 
and LEF-1) and cancer cells (TBP and NF-κB) were deactivated through blocking the 
recognition sequence of transcription factors with specific 8-10-ring PAs (Dickinson et 
al., 1998) (Wurtz et al., 2002).  
 Linear 4-ring PAs have been successfully used as antibacterial agents in vivo on 
gram-negative and gram-positive bacteria (Lou et al., 2002; Burli et al., 2004). 8-ring 
hairpin PAs with a second positive charge (Dp) on the C-terminus exhibited strong 
antifungal activity and no toxicity in mice (Marini et al., 2003). 
1.4.1 PAs Antiviral Activity against Human Papillomavirus (HPV):  
Human Papillomavirus (HPV) is a sexually transmitted virus that affects 20 
million Americans (National Center for HIV/AIDS, 2014). HPV is divided into high and 
low risk types. Low risk types produce warts and respiratory papillomatosis. High risk 
types cause cancer of various forms. The high risk HPV strains include 16, 18, 31, and 
35; HPV strains 16 and 18 cause 70% of HPV-related cancer (Chen et al., 2005) 
(Longworth & Laimins, 2004).  
The HPV16 viral genome is 7.9 kb (7904 bp) in size. The genome consists of two 
structural proteins, L1 and L2, and six proteins that play a role in viral reproduction (E1, 
E2, E4, E5, E6, and E7) (Fig. 1.11) (Longworth & Laimins, 2004). E1, E2, and E4 are 
responsible for regulation, replication, and expression of the HPV16 genome. E5 binds to 
the cellular growth factor receptors and epidermal growth factor receptors, thereby 
regulating cell growth and proliferation. E6 and E7 are oncoproteins responsible for 
transformation of normal cells into cancerous ones by aborting apoptosis and degrading 
p53 protein, which is responsible for tumor suppression (Longworth & Laimins, 2004).  
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Figure 1.11: Sequence of the HPV16 Genome (7904 bp). The HPV16 genome consists 
of the long control region (LCR) and genes for the expression of the two structural 
proteins (L1 and L2) and six regulatory proteins (E1, E2, E4, E5, E6, and E7). The LCR 
of HPV16 spans from 7154-83 bp.  
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There have been two vaccines developed in the last decade to protect people from 
HPV strains 6, 11, 16, and 18 (National Center for HIV/AIDS, 2014). Both of these 
vaccines prevent HPV infection but do not cure those already infected with HPV and do 
not prevent HPV from causing cancer. 
The first repeated study of anti-HPV PAs involved hairpin tandem PAs that 
targeted a 12 bp recognition sequence for the HPV E2 binding protein (important for 
HPV transcription) (Schaal et al., 2003). The binding of the tandem PA to the minor 
groove of the E2 recognition sequence (ACCN6GGT) prevented E2 protein from binding 
in the major groove due to conformational changes of the DNA (Schaal et al., 2003) 
(Hebner & Laimins, 2006).  
Further, PA1 and PA25 (Fig. 1.12) were designed to bind to AT rich sequences in 
and nearby the E1 and E2 binding protein sequences of the long control region (LCR) in 
HPV (Edwards et al., 2011).  PA25 exhibited a 3- to 12-fold better activity in the 
elimination of HPV16, HPV18, and HPV31 episomes than PA1 in monolayer cells and 
organotypic cultures (Edwards et al., 2011).   
The mechanism of the effect of PA25 on HPV16 episome elimination has been 
studied more recently. Activation of multiple DNA damage response pathways was 
observed upon treatment with PA25 (Edwards et al., 2013). Proteins from DNA damage 
response pathways, such as Mre11 and 9-1-1, which are responsible for repair, detection, 
and signaling of dsDNA breaks, were activated upon PA25 treatment. Therefore, hairpin 
PAs can be used as antiviral agents against HPV.   
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Figure 1.12: (A) Structure of the PA1 and PA25 Polyamides. (Top) Structure of PA1 
(dImPyPyβPyPyPy-γ-PyPyβPyPyPyPyβTa). (Bottom) Structure of PA25 
(dImPyPyβPyPyImβPyPy-γ-PyPyβPyPyPyβPyPyPyβTa) where Ta is 
CH3N(CH2CH2CH2NH2)2. (B) Effect of PA1 and PA25 on Episome Level of HPV16, 
HPV18, and HPV31. Adapted from (Edwards et al., 2011).  
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CHAPTER II 
MATERIALS AND METHODS 
2.1 Polyamide Materials: 
All polyamides (NV1028 and NV1042) were supplied by the James Bashkin 
Lab/NanoVir at the University of Missouri, Saint Louis, MO. All affinity cleavage 
reagents were made by Dr. G. Davis Harris, Jr., with other compounds made and purified 
by Dr. Kevin Koeller or Dr. G. Davis Harris, Jr.   
2.2 Polyamide Stocks: 
 PA1 stock was made by dissolving PA1 powder in 100 % DMSO. The 
concentration of the PA1 stock was determined by ultraviolet-visible spectrophotometer 
(UV-Vis) using 92,600 M
-1
cm
-1
 as the extinction coefficient at 305 nm. PA25 stock was 
made by dissolving PA25 powder in 100 % DMSO. The concentration of the PA25 stock 
was determined by ultraviolet-visible spectrophotometer (UV-Vis) using 147,400 M
-1
cm
-
1
 as the extinction coefficient at 305 nm. All the Kds for PA25 were determined with the 
assumption that the extinction coefficient for PA25 is 147,400 M
-1
cm
-1
. Later, the 
extinction coefficient was re-measured by Dr. Dupureur, and a new, more precise 
extinction coefficient of 91,700 M
-1
cm
-1
 was obtained. All of the Kds for PA25 were 
recalculated using new extinction coefficient of 91,700 M
-1
cm
-1
.   
2.3 DNA PCR Fragments of Study: 
 This study examines the long control region (LCR) fragment of the HPV 16 
genome. The entire HPV16 genome is 7904 bp. The LCR of HPV 16 starts at 7158 bp 
and ends at 83 bp (Fig. 1.11).  The region that was studied in this research was 7348-122 
bp. Since this sequence is 679 bp long and too large for accurate studies with capillary 
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electrophoresis (CE), this sequence was divided into two fragments, 7348-7798 bp (451 
bp) and 7662-122 bp (365 bp). To generate the 7348-7798 bp fragment, two primer 
oligomers were used: (top strand) 5’- FAM-ATT GTG TTG TGG TTA TTC AT-3’ and 
(bottom strand) 5’-HEX- CAT GTA TGA ACT AGG GTG AC-3’, where FAM indicates 
the fluorescein dye and HEX indicates the hexachlorofluorescein dye. To generate the 
7662-122 bp fragment by PCR, two primers were used: (top strand) 5’-FAM-TAA ATC 
ACT ATG CGC CAA CGC-3’ and (bottom strand) 5’-HEX- CCT GTG GGT CCT GAA 
ACA TTG-3’. 
In CE, only the first 250 nucleotides of the fragment could be analyzed; therefore, 
the 5’ends of each fragment were each labeled with a different dye: FAM dye on the top 
strand and HEX dye on the bottom strand. HEX dye is brighter the FAM dye; therefore 
there is more information observed from HEX dye labeled DNA strands than with FAM 
dye labeled DNA strands. Also, in CE, at least the first 50 nucleotides cannot be 
observed, and up to the first 80 nucleotides cannot be used in DNaseI footprinting due to 
the noise level. This did not cause any problems for the center of the 7348-122 bp 
fragment but only for the ends of the fragment.  
2.3.1 Preparation of 120mer: 
The binding studies of the NV1028 polyamide to isolated perfect match and 
single mismatch binding sites were performed on a 120 bp (120mer) piece of DNA that 
has one NV1028 binding site. This 120mer consists of 80 bp from the sequence of 
recombinant rat hormone-sensitive lipase (HSL) DNA (2161-2240 bp; Q1021-R1047 
a.a.). The binding site of NV1028 (W2GW7, where W=A or T) was inserted after the first 
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70 bp of the HSL DNA sequence (2130 bp). The whole sequence (90 bp) is shown below 
with the bold sequence representing the NV1028 binding site. 
2161 5’-CAGCCCGTGA CGCTGAAAGT GGTAGAGGAC CTGCCGCATG 
        GTTTCCTGAG CTTAGCAGCC CTGTGTCGTG TAGTATTATT AGACCGGCAG-3’,  
The first 50 bp are not observed in CE, therefore, this piece of artificial DNA had 
to be extended by PCR. This was accomplished through long primers: (top strand) 5’-A 
CTG AAG GAC CTG GGC CAG CCC GTG ACG CTG AAA GTG GTA G-3’ and 
(bottom strand) 5’-CAC AAC TCC GCG GCC TGC CGG TCC AAT AAT ACT ACA 
CGA-3’, where the bold text is the overlap with the 90 bp DNA fragment. The overall 
(120 bp) sequence is below, where bold text is the NV1028 binding site. 
2161 5’- ACTGAA GGACCTGGGC CAGCCCGTGA CGCTGAAAGT 
     GGTAGAGGAC CTGCCGCATG GTTTCCTGAG CTTAGCAGCC 
     CTGTGTCGTG TAGTATTATT GGACCGGCAG GCCGCGGAGT TGTG -3’  
 
To avoid multiple overlapping binding positions on the NV1028 binding site, the A 
nucleotide at the first position after the NV1028 binding site was mutated to a G 
nucleotide (in red; above sequence). 
 Single mismatches were introduced into the NV1028 binding site by bottom 
strand primer modifications. Single mismatches in the binding site were introduced at the 
following positions one at a time: WWGWWWWWWW, where the red colored 
nucleotides represent a mismatch to G nucleotide. 
2.4 Sequencing of the 7348-122 bp of HPV16: 
 The sequencing of the fragments was chosen appropriately for the end-chemistry 
generated. DNaseI generates a 3’ hydroxy terminus (Fig. 2.1). The sequencing method 
that mimics this DNA end chemistry is Sanger sequencing, where DNA polymerase 
incorporates dideoxyribonucleotides at the end of the strand (Sanger et al., 1977). 
Therefore, Sanger sequencing was used to determine cleavage positions in DNaseI  
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Figure 2.1: DNA Sequencing. (A) The products of the different sequencing, 
footprinting, and affinity cleavage methods assuming the 5’ DNA label and Nth 
nucleotide as the target. (B) The difference between Sanger and Maxam-Gilbert 
sequencing methods products’ position in CE vs. real position in the fragment. The top 
two panels have 5’ DNA labeled with FAM dye. The three bottom panels have 5’ DNA 
labeled with HEX dye. Adapted from (He et al., 2013).  
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footprinting data.  
 Affinity cleavage (AC) end-chemistry is the same as in Maxam - Gilbert 
sequencing (He et al., 2013). AC hydroxyl radicals destroy the phosphate bond between   
the deoxyriboses of the DNA backbone. Therefore, Maxam – Gilbert reactions were used 
to sequence AC data. 
2.5 PA1 (NV1028) and PA25 (NV1042) Footprinting with 7348-122 bp of HPV16: 
 DNaseI footprinting is a powerful in vivo and in vitro technique used to identify 
interactions between ligands and DNA (Fig. 2.2) (Bailly et al., 2005; Cardew & Fox, 
2010). In this study, the ligand was a polyamide (PA). DNaseI footprinting is used 
mainly for determining the position of the ligand binding sites on DNA and the binding 
affinities of the ligands to DNA (Trauger & Dervan, 2001).  
 DNaseI footprinting was performed on two DNA sequences from the LCR region 
of HPV 16 using NV1028 and NV1042 polyamides and on the 120mer for NV1028 
mismatch studies. The DNA was preincubated with polyamide for 4-6 hours at 37
o
C. The 
concentration of DNA was selected in such a way that the dissociation constant (Kd) of 
the PA was at least five times higher than the concentration of DNA used. The DNA/PA 
was preincubated in 10 mM Tris, 10mM CHAPS, a maximum of 2 % DMSO, pH 7.5-
8.0. After preincubation, the metal mixture needed for the DNaseI reaction was added; 
the 5x metal stock included 50 mM Tris, 25 mM Mg
2+
, 25 mM Ca
2+
, and 50 mM K
+
, pH 
7.5-8.0.  
 The reaction was initiated with 0.01-0.1 units DNaseI; the amount of DNaseI was 
dependent on the age of the enzyme, the DNA fragment, and DNA concentration. When 
DNA size is smaller (120 bp), more DNaseI had to be used (0.05-0.1 U DNaseI). If the  
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 Figure 2.2: Cartoon Depiction of DNaseI Footprinting. Radioactively or fluorescently 
labeled DNA is incubated with or without protein or small molecules. DNA undergoes 
cutting with DNaseI enzyme under single-hit conditions. If the protein or small molecules 
protect DNA, then DNaseI cannot access that position. The resulting products are 
analyzed by gel (CE). The DNA sequence that is protected appears on the gel as a blank 
spot because it is not cut. The DNA sequence that is not protected appears on the gel in 
the array of bands. Adapted from (Cardew & Fox, 2010).      
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concentration of DNA was small (10-50 pM), more DNaseI was used (0.5-0.1 U 
DNaseI). The mixture of DNaseI with the DNA fragment was incubated for 5 min at  
37
o
C (4 min for reactions with low concentrations of DNA (10-50 pM)) and quenched 
with 10 mM EDTA at 100
o
C for 2 min. Afterwards, the DNA was purified from DNaseI, 
PA, and salts with a Qiagen PCR Purification kit (Qiagen; Cat. No. 28104) for >100 bp 
DNA fragments and Qiagen MinElute purification kit (Qiagen; Cat. No. 28004) for <120 
bp fragments. The protocol for both of those Qiagen kits was followed as written with the 
exception that the DNA washing step was performed 2-3 times instead of once. The 
purified DNA fragments were submitted to capillary electrophoresis analysis at the 
Mizzou DNA Core for fragment analysis on an ABI 3730xl DNA Analyzer. 
 The results were analyzed using GeneMarker V1.97 software (Softgenetics LLC, 
State College, PA). Dissociation constants for PA footprints were determined the 
following way: first, the area of an electropherogram integration peak (I) in the footprint 
was divided by the area of a peak in the electropherogram that was not sensitive to PA 
concentration (R). Second, the polyamide fraction bound (θx) to DNA at each 
concentration of PA was determined by using the following formula:                               
1- 
                              
                                 
. Third, the θx was normalized to the highest θx in the 
array. Fourth, this normalization was plotted as the fraction of PA bound to DNA (θ) vs. 
PA concentration (Fig. 2.3). The plot was fit to the Hill (Eq.1) or the Langmuir (Eq.2) 
equation to generate an isotherm, where, Ka is the association constant, Lf is the free 
ligand concentration, N is the Hill coefficient. 
θ = (Ka [Lf]) 
N
 / (1 + (Ka [Lf]) 
N
) (Eq.1) 
θ = Ka [Lf] / (1 + Ka [Lf]) (Eq.2) 
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Figure 2.3: Determination of Binding Affinity. The fraction bound was plotted vs. PA 
(NV1028) concentration. Then the graph was fitted to the Langmuir equation (Eqn.2) 
(Top panel in graph) and Hill equation (Eqn.1) (Bottom panel in graph). In this case 
Ka is 0.4 nM
-1
 (Hill eqn.), Kd = 1 / 0.4 = 2.5 nM.   
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The conditions for all of the Kds reported for the 120mer DNA fragment with the 
NV1028 polyamide were 200 pM DNA, 10 mM Tris, 10 mM CHAPS, 2 % DMSO, and  
100x nt CT DNA, pH 7.5-8.0, unless otherwise specified. 
DNaseI has disfavors AT rich DNA sequences (Heddi et al., 2010). In 
experiments performed with DNaseI on the same piece of DNA (7348-122 bp) it was 
observed that depending on the batch and the age of the batch DNaseI disfavored 
different DNA sequences. In addition, it is individually discussed in Chapter III.  
2.6 Affinity Cleavage of PA1 (NV1028) and PA25 (NV1042) with 7348-122 bp of 
HPV16: 
 Affinity cleavage (AC) is a technique that is used to identify the position of the 
ligand when bound to DNA (Taylor, 1984). This technique depends on a ligand-EDTA 
conjugate that coordinates iron which produces hydroxyl radicals from atmospheric 
oxygen and water (Fig. 2.4). The polyamides of interest were synthesized for this purpose 
with EDTA on the 3,3-diamino-N- methyldiproprylamine (Ta) end. During the hydroxyl 
radical generation, Fe (II) oxidizes to Fe (III); for that reason, the reducing agent DTT 
(dithiothreitol) is added to initiate and prolong the life of the reaction. 
First, 5μM PA-EDTA∙Fe (II) complex was produced by mixing PA with 0.8 
equivalents of Fe (II) (Fe (NH4)2(SO4)2); the volume of DMSO did not exceed 50% of the 
total volume. Second, the 1 nM DNA fragment was mixed with 10 mM Tris, 10 mM 
CHAPS, and different amounts of PA-EDTA∙Fe (II) complex, pH 7.5-8.0.  
A high enough concentration of PA-EDTA∙Fe (II) complex was added to saturate all of 
the PA binding sites (5-100 nM of the PA-EDTA∙Fe complex). This mixture was 
incubated overnight at 37
o
C. 5 mM DTT was then added to initiate the reaction, and the  
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Figure 2.4: Affinity Cleavage Technique. (A) Polyamide- EDTA bound to the minor 
groove of DNA. The hydroxyl radical is generated as described in reaction below the 
DNA molecules. EDTA coordinates iron (Fe (II)) which uses oxygen from the 
atmosphere and water from the reaction to generate Fe (III) with hydroxide and hydroxyl 
radicals. Hydroxyl radicals cut the DNA phosphate backbone at that location (Fig. 2.1). 
(B) An example of capillary electrophoresis. The top panel is a control: DNA without the 
PA-EDTA conjugate. The bottom panel is DNA with 50 nM PA-EDTA conjugate. The 
affinity cleavage pattern emerges in a shape similar to a Gaussian distribution. Adapted 
from (Uil et al., 2003).    
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reaction was allowed to proceed for 3-4 hours at room temperature. The reaction was 
quenched and purified with a Qiagen PCR Purification Kit. Fragment analysis was 
analyzed by CE at the Mizzou DNA Core using an ABI 3730xl DNA Analyzer. AC data 
was analyzed using GeneMarker V1.97 software (Softgenetics LLC, State College, PA). 
The AC produced by 50 nM of the PA-EDTA∙Fe (II) complex was reported.   
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CHAPTER III. 
BINDING PROPERTIES OF POLYAMIDES PA1 AND PA25 TO THE 
LONG CONTROL REGION OF HPV16. 
3.1 Antiviral PAs:  
Polyamides are minor groove binding agents that were developed from the natural 
product Distamycin A. Distamycin A binds to the DNA minor groove with high binding 
affinity but low target specificity. Because of its low selectivity, it exhibits high 
cytotoxicity (Bialer et al., 1979). Distamycin A consists of three consecutive                   
N-methylpyrrole rings, but to increase the specificity, new monomer units were 
introduced: N- methylimidazole (Im), N-methylpyrrole (Py or P), γ-aminobutyric acid (γ-
turn), and β-Alanine.  The Dervan group developed the following rules for 6-8 ring 
polyamides: Im/Py recognizes G
.
C, Py/ Im recognizes C
.
G, Py/Py recognizes A
.
T or T
.
A, 
and β-alanine recognizes the same bases as N-methylpyrrole (Wang et al., 2001). 
Polyamides have been used to regulate the binding of  proteins to DNA and, as a 
result, to regulate protein expression (Schaal et al., 2003) (Dervan & Edelson, 2003). 
Larger hairpin polyamides (PA1, 12 rings; PA25, 20 rings) have also been shown to 
lower the amount of viral DNA copies in HPV 16, 18, and 31 infected cells (Fig. 1.12) 
(Edwards et al., 2011).  
3.2 Binding Properties of PA1 to the Minor Groove of DNA: 
PA1consists of 14 rings (Fig. 1.12). One of the 14 rings is imidazole, eleven rings 
are pyrrole rings, and the two remaining subunits are β-Ala (dImPyPyβPyPyPy-γ-
PyPyβPyPyPyPyβTa) (Fig. 1.12). To improve flexibility in PA1, two β-alanine residues 
were inserted (one on each side) of the hairpin- shaped PA. To obtain the hairpin 
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structure of the PA1 polyamide, a γ-turn was inserted into the middle of the PA sequence. 
PA1 recognizes a WWGWWWWWWW (W=A, T) DNA sequence according to the rules 
developed for 6-8-ring PAs.  
Polyamides can bind in either forward or reverse fashion to DNA sequences (Fig. 
1.9) (Urbach & Dervan, 2001). The forward fashion occurs when the 5’ end of DNA 
aligns with the N-terminal of the PA hairpin and the 3’ end of DNA aligns with the C-
terminal of the PA hairpin structure (Urbach & Dervan, 2001). According to previous 
studies performed with 6-ring polyamides, the forward fashion of binding is preferred 
(Urbach & Dervan, 2001). The PA1 polyamide is 1.5-2 times larger than the PAs that 
were used for studying this phenomenon; therefore, it was uncertain whether this 
guideline would apply to PA1-DNA binding.  
PA1 is designed to bind to the E1 binding sites of the long control region (LCR) 
(7156-84 bp) in the HPV genome to prevent viral replication.HPV 16 has one E1 
binding site (7896- 8) (Romanczuk & Howley, 1992) (Hegde & Androphy, 1998) 
(Doorbar, 2006) (Edwards et al., 2011). The IC50 of PA1 against HPV16 is 100 nM 
(Edwards et al., 2011).  
The PA1 binding sites were characterized by DNaseI footprinting and affinity 
cleavage. See Chapter II for experimental details. 
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3.2.1 Guidelines for Analysis of the Predicted PA1 Binding Sites vs. Real PA1 
Binding Sites:  
Figure 3.1 shows the affinity cleavage of PA1 with 7348-122 bp DNA fragment 
of HPV16. There were 34 AC patterns observed; some AC patterns consist of extended 
patters suggestion of overlapping binding events (AC 5, 14, 22, and 24). Prediction of 
the PA1 binding sites according to the rules developed by the Dervan lab (Appendix A) 
showed that one AC pattern can be rationalized by various possible predicted PA1 
binding sites, making the analysis complicated.   
Therefore, to simplify the analysis of PA1 binding to 7348-7798 bp, the following 
guidelines were used: first, up to 30% sequence discrepancy was allowed in the binding 
site (three mismatches for PA1). The second guideline was that a perfect match site was 
assumed to bind preferentially in the forward fashion over any other binding possibilities 
(Fig. 2.2). The rest of the mismatches in the binding site were ranked the following way: 
0MMF>0MMR=1MMF>1MMR=2MMF>2MMR=3MMF>3MMR=4MMF, where MM 
refers to mismatch, F refers to forward binding fashion, and R refers to the reverse 
binding fashion.  For each binding site sequence, the following limitations were placed 
for overlapping predicted PA binding sites to be bound at the same time: 0MMF, 
0MMR=1MMF, 1MMR=2MMF, 2MMR=3MMF, 3MMR=4MMF. The third guideline 
was that for every binding site with multiple binding possibilities, only the optimal 
binding possibility was considered in rationalizing the AC pattern. The final guideline 
was that if a double or triple mismatch site did not produce an AC, it was not investigated 
further. 
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Figure 3.1: Affinity Cleavage of 50 nM PA1-EDTA with 1 nM DNA 7348-122bp 
HPV16. Vertical black arrows represent the affinity cleavage produced by PA1. All of 
the assigned PA1 binding sites were observed by AC. The AC arrows are proportional to 
each other in size within one AC site, not to all AC sites, due to signal-to-noise difference 
between beginning and the end of the CE electropherogram. Solid horizontal arrows in 
between the DNA sequence lines represent PA1 binding in forward fashion. Dashed 
horizontal arrows under the DNA sequence lines represent PA1 binding in reverse 
fashion.  Horizontal arrows: black - perfect match, pink - single mismatch, purple - 
double mismatch, blue - triple mismatch, green - quadruple mismatch. A vertical, red, 
bold line with the number “1” in the box on top represents the beginning of the HPV16 
genome. 
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3.2.2 Affinity Cleavage with PA1 on 7348-122 bp HPV16 region: 
34 affinity cleavage (AC) sites were observed for PA1 (Fig. 3.1).  All AC sites 
have 3’ shifts consistent with minor groove binders (Schultz, 1982).   The discussion of 
the AC patterns is ordered by increasing mismatches in the binding sites. ACs 1, 13, 30-
32, and 34 can be rationalized by forward fashion perfect match binding sites only. The 
intensity of AC 2 was both extended and weak. This suggests that there are multiple 
possibilities for PA1 binding to this DNA sequence. AC 2 could be rationalized by a 
combination of overlapping forward and reverse perfect match sites as well as forward 
single mismatch sites. The aforementioned predicted PA1 binding sites could not be 
distinguished. AC 29 could be rationalized by either a reverse perfect binding site (7885-
7894 bp) or one of two possible forward single mismatch sites (7885-7894 bp or 7882-
7873 bp). 
ACs 5b-8, 14a, 17, 23-24a, and 28 can be rationalized by multiple forward single 
mismatch sites. AC 17 reproducibly forms two peaks; therefore, this pattern results from 
multiple PA1 binding modes.  
ACs 5, 14b, and 24b cannot be explained by PA1 binding to a single mismatch 
site only. Therefore, perfect match, double and triple mismatch binding possibilities are 
considered. AC 5 can be explained by one or both of the following possibilities: PA1 
bound to a forward triple mismatch site (7471-7462 bp) and/or PA1 bound to two single 
mismatch sites (7483-7492 bp and 7485-7494 bp). AC 14b is consistently a double peak 
AC, therefore, more than one PA1 molecule is bound to generate AC 14b. A forward 
triple mismatch binding site (7619-7628 bp) fits AC 14b better than any other option. A 
double mismatch binding site (7770-7779 bp) rationalizes AC 24b better than a single 
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mismatch binding site (7764-7755 bp), but both are considered because the preference 
between single and double mismatch sites for PA1 is yet to be fully studied. AC 24b is a 
perfect example of PA1 being indistinguishably bound to either a forward double 
mismatch site or a reverse single mismatch site (7770-7779 bp). 
 A forward double mismatch site is the only explanation for the 3’ part of ACs 3 
and 25 and for the full AC pattern for ACs 4, 16, and 27. PA1 bound to a forward or 
reverse double mismatch binding site and to a forward triple mismatch site can be used to 
rationalize the 3’ part of AC 3 and the full ACs 15 and 26. In many cases, reverse double 
mismatch sites could also be rationalized by forward triple mismatch sites. 
 ACs 11, 19, 20, and the 5’ part of AC 25 can be rationalized by forward triple 
mismatch sites only. In ACs 9 and 10, there are two peaks on the top strand; on the 
bottom strand, there is just one AC peak. This could be explained by differences in 
resolution (bottom strand vs. top strand). ACs 9 and 10 are unusual cases because AC 9 
can be explained by PA1 bound to a forward triple mismatch site while AC 10 can only 
be rationalized by a quadruple mismatch or by PA1 binding to the DNA in some other 
conformation (half hairpin or linear).  
 ACs 18 and 33 can be rationalized by PA1 bound to a forward quadruple 
mismatch site or to a reverse triple mismatch site; these cannot be distinguished.  
 AC 12 is a case where the top strand AC pattern was missing even though the AC 
pattern further down the sequence was present (AC 13) and the bottom strand AC was 
present. It can be explained by resolution problems associated with CE. This AC pattern 
could be rationalized only by a forward quadruple mismatch site.  
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 In the 7348-122 bp region of HPV16 genome, eight perfect match forward and 
four perfect match reverse PA1 binding sites were observed by AC. A number of single, 
double, triple, and, more rarely, quadruple mismatch sites that bound in both forward and 
reverse fashion were observed in this HPV16 region.  
3.2.3 PA1 DNaseI Footprinting with 7348-122 bp HPV16:  
 All of the PA1 binding sites that were observed by AC were also examined by 
quantitative DNaseI footprinting (Fig. 3.2; Table 3.1). The DNA sequence footprints are 
highlighted. The reference peaks were selected for optimal signal-to-noise ratios. 
Some sequences in the 7348-122 bp fragment of HPV16 were insensitive to 
cutting with the batch of DNaseI that was used to generate PA1 data (Fig. 3.2). DNaseI 
has a DNA sequence preference; it disfavors AT rich DNA sequences (Heddi et al., 
2010). In the case of the 7348-122 bp fragment from HPV16, it disfavored two sequences 
with four consecutive A nucleotides (7831-7840 bp and 7857-7866 bp). Another 
sequence that was disfavored by DNaseI was 7631-7640 bp. Even though the 7348-122 
bp fragment was divided into smaller fragments (7348-7798 bp and 7662-122 bp), the 
sequence 7761-7771 bp could not be cut, and therefore footprinted with DNaseI.  
 All of the Kds for perfect match sites ranged from 0.7 nM to 1.8 nM (Table 3.1). 
Similar Kds were obtained for PA1 with different fragments from HPV16 (2150-2672 bp) 
(He et al., 2014). Most Kds for single mismatch sites fell between 1.5 and 2.8 nM. This 
showed that PA1 had a good tolerance towards single mismatches in the binding site. 
Most Kds for the double mismatch sites ranged from 1.3 nM to 3.4 nM (Table 3.1; Fig.  
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Figure 3.2: DNaseI Footprinting with PA1 on 7348-122bp HPV16 Fragment. 
Vertical black arrows represent AC produced by PA1. The vertical red bold line with 
number “1” in the box on top represents the beginning of the HPV16 genome. The bold 
letters in boxes represent the nucleotides that were picked for determination of the 
dissociation constants. The letter in pink represents the reference peak. Yellow highlights 
DNA sequences denote a complete DNaseI footprint at 5 and 10 nM PA1 and 200 pM 
DNA fragment. Grey highlights DNA sequences denote a complete DNaseI footprint at 
20-40 nM PA1 with 200 pM DNA fragment. The same figure with all of the predicted 
PA1 binding sites can be found in Appendix A. 
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Table 3.1: PA1 Binding Sites Sequences and Dissociation Constants. 
 
Continued, next page. 
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Table 3.1: Continued. 
 
Letters in red represent mismatches. The italicized numbers represent PA1 bound in 
reverse fashion. Binding affinities were assigned for binding sites if their respective 
integration peaks were contained within their PA1 binding sequence. Certain binding 
sites are highlighted grey due to low precision caused by high Hill coefficients and not 
enough measurements near their Kds. Bold G denotes the nucleotide where the PA1 
imidazole unit binds.  
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Figure 3.3: Binding Affinities and Hill Coefficients of PA1 (NV1028). The DNaseI 
footprinting was performed on the 7348-122 bp DNA fragment from HPV16. (A) Plot of 
the the Kds determined for PA1 (NV1028) vs. the number of mismatches that occurred in 
the PA1 binding site. (B) Plot of the Hill coefficient determined for PA1 (NV1028) vs. 
the number of mismatches that occurred in the PA1 binding site. This figure does not 
include Kds and Hill Coefficients that are highlighted grey in the table. 
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3.3A). Therefore, PA1 can often bind double mismatch sites without an energetic penalty. 
There is a single mismatch site with a binding affinity of 13.1 nM which is 3-4-fold 
higher than the average affinity for the single mismatch sites. The binding affinity of 13.1 
nM could be the result of the binding affinity being determined at the mismatch 
nucleotide. The peak (7827 bp) for determination of binding affinity was picked because 
it had good signal-to-noise ratio. There were several double mismatch sites with Kds 
between 10.3 nM (7770-7779 bp and 7782-7773 bp) and 19.5 nM ± 8 nM (7812-7821 
bp). We do not believe the high Kd is due to where the footprint was integrated because 
other sites (7466-7475 bp and 7649-7658 bp) that showed low nM binding affinity were 
quantitated similarly. We also do not believe that the poly A tract that the binding site 
consists of is involved. The second reason that could be ruled out was the bending of the 
DNA. The 7770-7779 bp and 7782-7773 bp PA1 binding site has three consecutive A 
nucleotides, which can cause a bend in the DNA, leading to a poor fit for PA1 to the 
minor groove. However, the binding site 7466-7475 bp also has four consecutive A 
nucleotides, and there is no effect on the binding affinity for this site. Triple mismatch 
sites displayed slightly higher Kds (2.1-5.0 nM, 10.3 nM, 10.8 nM). There were 
quadruple mismatch binding sites observed where PA1 bound with Kds ranging from 3.5 
nM to 7.3 nM. In conclusion, PA1 can bind sites containing up to 4 mismatches with high 
affinity.  
The Hill coefficient for single, double, triple, and quadruple mismatch sites was 
2.0 on average (Fig. 3.3B). This phenomenon was observed previously with 8-ring 
hairpin PAs (Bashkin et al., 2013). It was observed that area of the peaks in 7572-7547 
bp region of DNA decreases at 5 nM PA1 more than 50% in comparison to the same 
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peaks at 2 nM. Isotherms had a sigmoidal appearance and had Hill coefficient between 
3.8-5.1, but precise Hill coefficients still need to be determined (Fig. 3.4; Appendix B). 
In Figure 3.4 (Right) it can be observed that peaks 7570 (222.7), 7562 (230.5), and 7556 
(237) disappear more than 50% between PA titrations 2 and 5 with respect to peak 7579 
(217.2), while Figure 3.4 (Left) peak disappears gradually (less than 50%) between 
titrations 2 and 5 in reference to peak 7872 (150.5). This shows a fast change between 
bound and unbound state, leading to the conclusion that these sites can be cooperative.  
 In the 7348-122 bp HPV16 fragment, there were three stretches of DNA sequence 
that solely consisted of A/T nucleotides (7488-7499 bp, 7654-7666 bp, and 7888-7900 
bp) which means PA1 could have bound it in multiple binding possibilities in forward or 
reverse fashions. In the case of the 7654-7666 bp and 7888-7900 bp DNA sequences, the 
PA1 did not bind to them at all.  
3.2.4 PA1 Mismatch Investigation:  
 6-8-ring PAs have a strong preference (10-100-fold) for perfect match binding sites 
over single mismatch binding sites (Dervan & Edelson, 2003). From the above study, it 
was observed that PA1 (14-rings) can bind to single mismatch binding sites without a 
decrease in binding affinity (less than 2-fold) compared to perfect match sites. Therefore, 
the PA1 polyamide binding affinities to single mismatch binding sites was investigated. 
The DNA recognition sequence for PA1 was inserted into the GC rich hormone sensitive 
lipase gene to isolate the binding site. The perfect match site (TAGTATTATT) that PA1 
bound with the lowest dissociation constant (0.7 nM) was chosen for single mismatch 
studies.  
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Figure 3.4: Cooperative PA1 binding site. PA1 was gradually (0, 1, 2, 5, 10 nM) 
titrated into the 200 pM 7662-122 bp (left) and 7348-7798 bp (right) fragment.  (Left) 
PA1 binding to the 7882-7873 bp (140-150 in CE electropherograms), the 132-153 length 
region is presented in electropherogram. The peaks of interest are 7878 bp (144) (Kd 8.1 
nM; Hill Coeff. 2.8) and 7880 (142) (Kd 4.7 nM; Hill Coeff. 2.8). Compare these peaks to 
150.5 peak. (Right) PA1 binding to the 7577-7532 bp (215-260 in CE 
electropherograms) is presented in electropherograms. The region 7570- 7547 bp (223-
246) is of interest, precisely peaks 7556 (237) (Kd 3.9 nM; Hill Coeff. 3.8), 7562 (230.5) 
(Kd 4.7 nM; Hill Coeff. 5.0), and 7570 (222.7) (Kd 4.6 nM; Hill Coeff. 5.1). The 
reference peak for this fragment is 7579 bp (217.2). 
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3.2.4.1 DNaseI Footprinting – DNA Concentration Adjustment:   
 During the study of the effect of a PA1 single mismatch on the 120mer DNA  
fragment, it was observed that the polyamide bound very tightly. The studies started by 
exploring a perfect match site for the PA1 dissociation constant on the 120mer DNA 
fragment. The 120mer DNA fragment DNaseI footprinting was performed as discussed in 
the footprinting protocol unless stated otherwise. When 200 pM DNA was used, the Kd 
was approximately 100 pM (Fig. 3.5).Therefore, the concentration of DNA was 
decreased to 50 pM, and the Kd decreased to ~15 pM. The concentration of DNA was 
again reduced to 10 pM, and the Kd decreased to 1 pM.    
Because 10 pM DNA was at the limit of the lowest concentration of DNA that 
could be successfully purified with Qiagen PCR Purification Kit and afterwards analyzed 
with CE, changes to the reaction conditions were explored. Removal of the CHAPS 
detergent reduced the Kd up to 3-fold in some cases. The problem that arose from 
removal of the CHAPS detergent was that the DNA fragments purified with Qiagen PCR 
Purification Kit were purified in lower concentrations, which affected the CE results. 
Therefore, the following strategy was applied. 
Calf thymus DNA (CT DNA) was used as a carrier. The amount of CT DNA 
added to the reaction was calculated in nucleotides. Sonicated CT DNA has a range of 
fragments between 587-831 bp, with an average of 709 bp (1418 nt) (Sigma Aldrich). 
The amount of CT DNA added in nucleotides was 1-fold to 100-fold more than the 
labeled 120mer DNA fragment in nucleotides. The 100-fold addition of CT DNA to the 
120mer DNA fragment increased the Kd from 100 pM to 400-800 pM for the 200 pM  
120mer DNA fragment (Fig. 3.5). This affinity range made the study more feasible.  
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Figure 3.5: Examples of the Kd dependence on the DNA/PA concentration. (A) At 
200 pM 120mer DNA, Kd was ~100 pM. (B) At 50 pM 120mer DNA, Kd was ~10 pM. 
(C) At 10 pM 120mer DNA, Kd was ~1 pM. (D) At 200 pM 120mer DNA with 100-fold 
more calf thymus DNA by nucleotide concentration, Kd was ~ 400-800 pM.  
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3.2.4.2 PA1 Single Mismatch Binding Sites Investigation: 
 The first design of the 120mer with one PA1 binding site with mismatch A and B 
(Scheme 1) showed a longer footprint a just for one PA1 binding site. This happened 
because PA1 had two overlapping binding sites. Therefore, a nucleotide flanking the 
NV1028 binding site was mutated to G nucleotide to avoid multiple PA1 binding 
possibilities (Materials and Methods 2.2.1). The data was reported for both 120mers 
with no difference in the binding affinity (Table 3.2).  
 To sample single mismatches in the binding site, guanine nucleotides were replaced 
at every other W nucleotide in the binding site (Scheme 1). As a result, five different 
single mismatch binding sites were studied:  
WG   
E             A       B        C       D             
W W G  W W W W  W W W       
         Im-Py-Py-β-Py-Py-Py 
Ta-β-Py-Py-Py-Py-β-Py-Py 
W W C  W W W  W W W W 
Scheme 1: Position of Mutation in PA1 Binding Site for Single Mismatch Studies. W 
represents an A or T nucleotide. Red represents the nucleotide that was mutated to a 
guanine nucleotide.    
 All the dissociation constants were very similar; the maximum difference 
compared to the perfect match binding site dissociation constants was 1.3 fold (Table 
3.2).  
In conclusion, PA1 binds an isolated single mismatch site without any energetic 
penalty relative to a perfect match site.  
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Table 3.2: PA1 (NV1028) Single Mismatch Studies. 
Sequence 
WWGWWWWWWW X 
Kd 
[pM] 
 
Fold 
change 
TAGTATTATT A 650 1.0 
TAGGATTATT A 700 1.1 
TAGGATTATT G 710 1.1 
TAGTAGTATT A 800 1.2 
TAGTAGTATT G 830 1.3 
TAGTATTGTT A 740 1.1 
TAGTATTATG A 750 1.2 
GAGTATTATT A 700 1.1 
Red colored nucleotide represents the nucleotide of mismatch in the PA binding site. The 
nucleotide number eight (A; G in one case) was used for dissociation constant 
determination. Fold change was determined as a single mismatch Kd divided by the 
perfect match Kd. X is the flanking nucleotide that was mutated from A to G to avoid 
multiple PA1 binding possibilities to one binding site. Kds were determined in presence 
of 100x Calf Thymus DNA by nucleotide count comparing to the labeled 120mer DNA 
(1 nM 120mer duplex would have had 2400 nM nucleotides of CT DNA. This would 
equal 1.7 nM CT DNA duplex assuming that the length of CT DNA is 700 bp). 
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3.2.5 Studies of the PA1 with Chiral γ-Turn: 
 As mentioned in Chapter I, the presence of the chiral α-amino substituted                   
γ-aminobutyric acid in a hairpin polyamide influences the preference of the polyamide to 
bind in a forward or reverse fashion. The R enantiomer of the α-amino substituted            
γ-aminobutyric acid in 8-ring PAs influenced PA to bind in the forward fashion (Herman, 
1998; Swalley, 1999; Zhang et al., 2006a; Tsai et al., 2007). The S enantiomer of the      
α-amino substituted γ-aminobutyric acid in 8-ring PAs influenced PAs to bind the reverse 
fashion or to bind equally well in either fashion.  
 The R enantiomer of α-amino substituted γ-aminobutyric acid (Fig. 3.6A) of PA1 
was investigated by the affinity cleavage technique. The AC by PA1 that had a chiral turn 
did not change relative to the AC of PA1 without an achiral turn (Fig. 3.6B). It is likely 
that the large size of PA1 (relative to the 6-8-ring PAs) makes turn chirality less 
influential on the binding fashion.  
Another possibility could be that PA1 already had a preference for the forward 
fashion of binding. Therefore, incorporation of a chiral turn in PA1 did not affect the PA1 
binding fashion. 
3.3 Binding Properties of PA25 to the Minor Groove of DNA: 
PA25 PA was designed to bind to AT-rich sequences of the LCR of HPV16, 
HPV18, and HPV31 to inhibit HPV protein E1 from binding to the LCR region. In vivo, 
it was shown that PA25 is 3-fold more effective against HPV16 and HPV 31, and 12-fold 
more effective against HPV18 than NV1028 (Fig. 1.12).  
PA25 consists of 20 rings: 2 imidazoles, 4 internal β-Ala, and 14 pyrrole rings 
(dImPyPyβPyPyImβPyPy-γ-PyPyβPyPyPyβPyPyPyβTa) (Fig. 1.12). According to the  
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Figure 3.6: PA1 with the R Enantiomer of the α-Amino Substitution on the γ-Amino 
Butyric Acid. (A) Structure of the R enantiomer of α-amino (red) substituted γ-
aminobutyric acid on PA1. (B) The electropherograms of the 50 nM PA1 AC with or 
without the α-amino substation of the γ-aminobutyric acid with 1 nM 7348-7798 bp 
fragment. The above electropherograms are the representation of duplicate experiment.  
 
 
A 
B 
AC by PA1-EDTA with chiral turn 
AC by PA1-EDTA without chiral turn 
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PA binding rules to DNA that were developed for 6-8-ring PAs, PA25 binds to the 5’-
WWGWWWWWGWWWW-3’ (W= T or A) DNA sequence.  
6-8-Ring PAs prefer to bind in the forward fashion. PA25 is 2.5-3.3 times larger, 
therefore, it is unknown if PA25 still follows this preference or not.  
The PA1 binding sites were characterized by DNaseI footprinting and affinity 
cleavage. See Chapter II for experimental details. 
3.3.1 Guidelines for Analysis of the Predicted PA25 Binding Sites vs. Real PA25 
Binding Sites:  
 Although there are no perfect PA25 binding sites in this region of the genome, 
PA25-EDTA affinity cleavage with 7348-122 bp HPV16 DNA fragment showed 31 AC 
patterns that are close to each other and in cases ACs #6, 17, 18, 22, 25, and 28 overlap 
(Fig. 3.7). According to the rules developed to predict PA binding sites many predicted 
PA25 binding sites can explain one AC pattern.  
To simplify analysis of the AC data, the same guidelines were used as for 
NV1028 with the following exception: 30% sequence discrepancy in the binding site 
correlates to a quadruple mismatch for PA25; quadruple mismatch sites that were bound 
in the reverse fashion were added. For each binding site sequence, the following priorities 
were placed for predicted PA binding sites to bind at the same time: 1MMF=1MMR, 
2MMF=2MMR, 3MMF=3MMR, 4MMF=4MMR. The final guideline was that if a triple 
or quadruple mismatch site did not produce AC, it was not investigated further. 
3.3.2 Affinity Cleavage with PA25 on 7348-122 bp HPV16 region:  
At 50 nM PA25-EDTA complex with 1 nM DNA, 31 AC sites were identified  
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Figure 3.7: Affinity Cleavage of 50 nM PA25-EDTA with 1 nM DNA 7348-122bp 
HPV16. Vertical black arrows represent the affinity cleavage produced by PA25. 
Horizontal arrows represent PA25 binding sites predicted and observed by AC. The AC 
arrows are proportional to each other in size within one AC site, not to all AC sites, due 
to signal-to-noise difference between beginning and the end of the CE electropherogram. 
Horizontal arrows: pink - single mismatch, purple - double mismatch, blue - triple 
mismatch, green - quadruple mismatch. Solid horizontal arrows in between the DNA 
sequence lines represent PA binding in forward fashion. Dashed horizontal arrows under 
the DNA sequence lines represent PA binding in reverse fashion. A vertical, red, bold 
line with number “1” in the box on top represents the beginning of the HPV16 genome. 
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(Fig. 3.7). All of the AC had a 3’ shift consistent with a ligand bound in the minor groove 
of DNA (Schultz, 1982). The ACs are discussed with increasing mismatch binding sites. 
The 3’ part of AC 1 can be rationalized by a forward single mismatch binding 
site. AC 25b can be rationalized by a forward single mismatch binding site, but because 
the AC is elongated, a forward double mismatch binding site (7900-7888 bp) was 
considered as part of this AC as well. The 5’ part of AC 1 and AC 25a can be 
rationalized by a reverse single mismatch binding site or a forward double mismatch 
binding site; those two are indistinguishable in AC or DNaseI footprinting. ACs 6c, 14, 
25a, 26, and 27 can be rationalized by forward double mismatch binding sites with no 
other participating binding sites involved. 
The ACs that can be explained either by forward or reverse double mismatches or 
by forward triple mismatch binding sites are ACs 5 and 17c. AC 5 can be rationalized by 
forward double mismatch binding sites or triple mismatch binding sites. The long tail of 
AC 5 can be rationalized by forward triple mismatch binding sites that bind to the same 
sequence as the reverse double mismatch binding sites (7493-7481 bp and 7495-7583 
bp). Forward double mismatch binding sites do not fit well for AC 17c; therefore, a 
forward triple mismatch site was used to rationalize AC 17c as well. Because AC 28a has 
a slightly elongated tail at the 3’ end of the bottom strand, a forward double mismatch 
(26-14 bp) and forward quadruple mismatch (30-42 bp) binding sites were used to 
rationalize it. The best way to rationalize AC 6b is by forward and/or reverse double 
mismatch binding sites. AC 13 can be rationalized by forward and/or reverse double 
mismatch sites because they bind to the same DNA sequence.     
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Triple and quadruple mismatch binding sites were used to rationalize 17 out of 31 
AC generated by PA25. This means that from AC, we can draw a conclusion that PA25 
can tolerate more than 25% sequence discrepancy in its binding site.  
ACs 4 (3’ part top strand), 6a, 10, 11, 17a, and 20 can be rationalized using 
forward and reverse triple mismatch binding sites only. 5’ part of AC 10 and AC 19 can 
be rationalized by reverse triple mismatch binding sites. ACs that can be rationalized with 
triple or quadruple mismatch bound by PA25 are ACs 12, 18, 19, 22, and 30. The 
forward quadruple mismatch binding sites were used to rationalize this AC because those 
sequences are also reverse triple mismatch binding sites. It is unknown which PA25 
binding mode is preferred. To rationalize AC 22a, the triple mismatch binding site was 
involved but the triple mismatch binding site does not align perfectly with the top strand 
AC; one would expect the top strand AC to be closer to the 3’ end of the top strand for 
minor groove binder. 
ACs 2-4, 8, 9, 17b, 21, 23, 24, 28, 29, and 31 can be rationalized with quadruple 
mismatch binding sites bound in forward or reverse fashion. 3’ part of AC 2, AC 24, and 
AC 28b can be rationalized with reverse quadruple mismatch binding sites only.  
ACs 7, 15, and 16 cannot be rationalized by any predicted binding sites up to a 
quadruple mismatch. Therefore, they could have been generated with PA bound in the 
manner that does not follow PA binding rules that were developed by Dr. Dervan’s group 
or by a PA bound in a conformation other than a hairpin.  
3.3.3 PA25 DNaseI Footprinting with 7348-122 bp HPV16:     
 DNaseI footprinting technique was used to confirm all of the AC predicted 
binding sites (Fig 3.8; Table 3.3).  
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Figure 3.8: DNaseI Footprinting of PA25 on 7348-122bp HPV16 Fragment. Vertical 
black arrows represent AC produced by PA25. The bold letters with box around them 
represent the nucleotides that were picked for determination of the dissociation constants. 
The letter in pink highlight represents the reference peak. Yellow highlights DNA 
sequences denote a complete DNaseI footprint at 2 and 5 nM PA25 and 200 pM DNA 
fragment. Grey+Yellow highlights DNA sequences denote a complete DNaseI footprint 
at 10 nM PA25 and 200 pM DNA fragment. Green color represents DNA sequence that 
cannot be observed because of the fragment division. A vertical, red, bold line with 
number “1” in the box on top represents the beginning of the HPV16 genome. The same 
figure with all of the predicted PA25 binding sites can be found in Appendix C. 
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Table 3.3: PA25 Binding Sites Sequences and Dissociation Constants. 
 
 
Continued, next page. 
 
a
(He, 2011). Letters in red represent mismatches. Bold letters in sequence represent the 
PA25 imidazole units binding nucleotides. The italicized numbers represent PA1 bound 
in reverse fashion. 
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Table 3.3: Continued. 
 
 
Continued, next page. 
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Table 3.3: Continued. 
 
Binding affinities were assigned for binding sites if their respective integration peaks 
were contained within their PA1 binding sequence. Entries 58-67 don’t have any 
sequence assigned because there was no AC observed for the binding sites that produced 
footprint. All of the binding affinities were determined at 200 pM DNA using 147,400 M
-
1
cm
-1
 as extinction coefficient for PA25. *All of the Kds listed under 91,700 M
-1
cm
-1
 as 
extinction coefficient were calculated from Kds determined using 147,400 M
-1
cm
-1
 as 
extinction coefficient for PA25. 
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The sequence 7857-7870 bp was consistently not cut well by DNaseI on the 
bottom and top strands by either of the batches of DNaseI that were used in the course of 
the PA1 and PA25 studies. For this reason, the integration sites are scarce and the binding 
affinity for the 7853-7865 bp region was not determined, and only one binding affinity 
was determined for 7865-7877 bp binding site. With the batch of DNaseI that was used 
for PA1 DNaseI footprinting studies, DNaseI did not cut well in the 7831-7840 bp and 
7631-7640 bp regions besides the 7857-7866 bp region, as mentioned before. In the case 
of the batch of DNaseI that was used for PA25, these aforementioned sites were cut; 
therefore there is a DNaseI cutting efficiency difference between different batches of 
DNaseI.  
Most of the observed binding sites for PA25 are double, triple, and quadruple 
mismatch sites. The only perfect match site has a dissociation constant of 1.9 nM. The 
single mismatch site has a dissociation constant of 1.1 nM. The double mismatch sites 
have Kds in the range of 1.1 nM to 5.5 nM, but thirteen of the seventeen determined Kds 
for double mismatch sites fall in the range of 1.1 nM to 2.3 nM (Fig. 3.9B). The triple 
mismatch sites have the same Kd range as double mismatch sites with 20 out of 21 sites 
have dissociation constants between 1.1 nM and 2.6 nM. The quadruple mismatch sites 
are the most abundant mismatch sites in this fragment. The range of dissociation 
constants for quadruple mismatches is wider, ranging from 1.1 nM to 11.1 nM. Still, most 
of the Kds fell in the range between 1.1 nM and 3.5 nM, but more Kds compared to lower 
mismatch sites had higher (weaker) values.  As was observed by footprinting with PA25 
(Figure 3.8), most of the fragment is occupied by PA25 at 10 nM.  
The DNA sequence 7611-7650 bp was covered by PA25 according to DNaseI  
76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 3.9: Binding Affinities and Hill Coefficients of PA25 (NV1042). The DNaseI 
footprinting was performed on the 7348-122 bp DNA fragment from HPV16. (A) Plot of 
the Kds determined for PA25 (extinction coefficient 147,400 M
-1
cm
-1
) vs. the number of 
mismatches that occurred in the PA25 binding sites. (B) Plot of the Kds calculated for 
PA25 using extinction coefficient 91,700 M
-1
cm
-1
 vs. the number of mismatches that 
occurred in the PA25 binding sites. (C) Plot of the Hill coefficients determined for PA25 
vs. the number of mismatches that occurred in the PA25 binding site sites. Zero mismatch 
Kd comes from (He, 2011). 
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footprinting, but no ACs were observed for this region. This could have occurred because 
many PA25 molecules bound to the same sequence not allowing enough cutting to be 
produced in AC (Appendix C). 
The Hill coefficients for the single, double, triple, and quadruple mismatch sites 
were in the range of 1.2 to 3.3 (Fig 3.9B). The Hill coefficient range increased as the 
number of mismatches increased. Possibly, as more PA molecules bind the DNA, DNA 
structure changes, allowing less-favorable PA binding sites to be bound by PA25. 
3.3.4 PA1 and PA25 Cooperativity: 
 As described above (Chapter 3.2.3 and 3.3.3), PA1 and PA25 bind to perfect and 
mismatch sites with an average Hill coefficient of 2.0. The Hill coefficient is a 
representation of the cooperativity between two or more interacting molecules. If the Hill 
coefficient is less than 1, the cooperativity is negative which means binding of one 
molecule decreases the binding affinity of the next binding molecule. If the Hill 
coefficient is equal to 1, then there is no cooperativity, and molecules bind independently. 
If the Hill coefficient is greater than 1, there is positive cooperativity which means 
binding of one molecule facilitates the binding of the next molecule.  
 Cooperativity is observed in several systems that bind DNA: proteins bind 
cooperatively to the major groove of DNA through protein-protein interactions (Ptashne, 
1992; Raumann, 1994).  Transcription λ repressors bind to two DNA binding sites 
cooperatively through interactions in carboxyl domains (Ptashne, 1992). The λ repressor 
recruits and binds RNA polymerase cooperatively through the amino domain. Another 
example of cooperative protein dimer binding to DNA is observed in the case of MetJ 
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repressor. Two MetJ dimers bind to DNA through tetramer formation by antiparallel β-
sheets binding cooperatively in the major groove of DNA (Raumann, 1994).  
 Cooperativity is observed when two linear PAs bind anti-parallel to one binding 
site in the minor groove of DNA (Wade et al., 1993; Kelly et al., 1996). The Hill 
coefficient of this binding was between 1.9 and 2.0, which indicates positive 
cooperativity. There was no discussion about the reasons for the cooperativity of linear 
PAs bound to one binding site in either of the publications that reported this data. There 
was also cooperativity reported for extended hairpin PAs that have two ring units that are 
unpaired (Fig. 3.10) (Trauger, 1998). Upon two hairpins binding to adjacent binding 
sites, two rings from each extended hairpin would form an anti-parallel dimer. The Hill 
coefficient for this extended hairpin PA was not reported and the reasons for the observed 
cooperativity were not addressed; it was just reported that the isotherms fit well to 
cooperative binding isotherms. A slight cooperativity was observed as well with 8-ring 
hairpin PAs (Bashkin et al., 2013).  
 PA1 exhibits cooperativity upon binding characteristic of linear PA dimers 
binding to the minor groove (Fig. 1.5). This could be explained two ways: the 
cooperativity was observed and not reported for hairpins bound to DNA, or PA1 binds in 
unknown fashion that is not published in literature yet.   
 We observed Hill coefficients higher than 2.0 for both for the PA1 and PA25. 
This was rationalized by the fact that, as noted by Chen et al., upon DNA binding, a 
Distamycin A dimer changes the width of the minor groove from 5.7 Å (B-DNA) to 7.7 
Å while the width of the major groove stays almost the same (11.3 Å for B-DNA and 
11.7 Å for B-DNA with a Distamycin A dimer bound) (Chen et al., 1994). It is also noted  
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Figure 3.10: Extended Hairpin PA Dimer (ImPyβImPyPyγPyImPyβ). Adapted from 
(Trauger, 1998). 
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by Oguey et al., that the DNA minor groove width depends on the sequence it is 
composed of, therefore influencing interaction with DNA minor groove (Oguey et al., 
2010). The speculation is that PA1 or PA25 binding in the minor groove of DNA widens 
the minor groove resulting in the next PA molecule binding an adjacent region of the 
minor groove more easily. It is also known that 8-ring PAs bend DNA (Wang et al., 
2012). It is possible that PA1 and PA25 binding to higher affinity sites bends the DNA 
such that lower affinity binding sites are filled out by PA1 or PA25 with less energetic 
penalty. To follow up on this issue, future studies need to be performed.   
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 Appendix A: AC and DNaseI Footprinting with PA1 on 7348-122bp HPV16 
Fragment. Vertical black arrows represent AC produced by PA1. The bright red 
numbers with # in front are the AC sites numbering. The AC arrows are proportional to 
each other in size within one AC site, not to all AC sites, due to signal-to-noise difference 
between beginning and the end of the CE electropherogram. All of the assigned PA1 
binding sites were observed by AC. Horizontal arrows: black - perfect match, pink - 
single mismatch, purple - double mismatch, blue - triple mismatch, green - quadruple 
mismatch. Solid horizontal arrows in between the DNA sequence lines represent PA1 
binding in forward fashion. Dashed horizontal arrows under the DNA sequence lines 
represent PA1 binding in reverse fashion. The vertical red bold line with number “1” in 
the box on top represents the beginning of the HPV16 genome. The bold letters in boxes 
represent the nucleotides that were picked for determination of the dissociation constants. 
The numbers in dark red are the Kds nM. The letter in pink represents the reference peak. 
Yellow highlights DNA sequences denote a complete DNaseI footprint at 5 and 10 nM 
PA1 and 200 pM DNA fragment. Grey highlights DNA sequences denote a complete 
DNaseI footprint at 20-40 nM PA1 with 200 pM DNA fragment. 
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 Appendix B: Isotherms with High Hill Coefficient. (Left) The isotherm represents the 
electropherograms from Fig. 3.4 (Left) peak 7880 (142.3), which do have cooperativity 
(Hill coefficient = 2.1), but not as drastic as Fig. 3.4 (Right). (Right) The  isotherm 
represents the electropherograms from Fig. 3.4 (Right) peak 7562 (230.5), which do have 
high cooperativity (Hill coefficient = 7.1).  
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 Appendix C: AC and DNaseI Footprinting with PA25 on 7348-122bp HPV16 
Fragment. Vertical black arrows represent AC produced by PA25. The bright red 
numbers with # in front are the AC sites numbering. The AC arrows are proportional to 
each other in size within one AC site, not to all AC sites, due to signal-to-noise difference 
between beginning and the end of the CE electropherogram. All of the assigned PA1 
binding sites were observed by AC. Horizontal arrows: pink - single mismatch, purple - 
double mismatch, blue - triple mismatch, green - quadruple mismatch. Solid horizontal 
arrows in between the DNA sequence lines represent PA25 binding in forward fashion. 
Dashed horizontal arrows under the DNA sequence lines represent PA25 binding in 
reverse fashion. The vertical red bold line with number “1” in the box on top represents 
the beginning of the HPV16 genome. The bold letters in boxes represent the nucleotides 
that were picked for determination of the dissociation constants. The numbers in dark red 
are the Kds nM. The letter in pink represents the reference peak. Yellow highlights DNA 
sequences denote a complete DNaseI footprint at 2 and 5 nM PA25 and 200 pM DNA 
fragment. Grey highlights DNA sequences denote a complete DNaseI footprint at 10 nM 
PA25 with 200 pM DNA fragment. Green colored letters represent DNA sequence not 
observed in the DNaseI footprinting. 
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CHAPTER IV 
SERINE HYDROLASES. 
4.1 Introduction to Serine Hydrolases: 
 Serine hydrolases are the largest class of the enzymes (~250 enzymes) with 1% of 
all of human genes coding for them (Lander et al., 2001). This class consists of the serine 
proteases and metabolic serine hydrolases (mSH) (Simon & Cravatt, 2010). mSH consist 
of such enzymes as esterases (acetylcholinesterase and butyrylcholinesterase), lipases 
(hormone sensitive lipase and monoacylglycerol lipase), amidases (fatty acid amide 
hydrolase), and peptidases. More than 60% of mSH feature the α/β fold, which is 
characterized by 7 β-sheets and 8 α-helices (Fig. 4.1) (Holmquist, 2000). Serine is the 
conserved active site amino acid that serves as the nucleophile on a substrate. The acyl-
enzyme intermediate is then hydrolyzed from the enzyme by water/hydroxide, which 
leads to enzyme regeneration (Fig. 4.2). The active site serine is activated through a 
proton relay that involves histidine and glutamic acid or aspartic acid. Because of the 
abundance of serine hydrolases and their vital role in biochemistry, they are drug targets 
for many diseases such as diabetes (hormone sensitive lipase) (Henness & Perry, 2006; 
Thornberry & Weber, 2007), obesity, Alzheimer’s disease (acetylcholinesterase) (Racchi 
et al., 2004), Parkinson’s disease, inflammations, hypertension, and cancer. As a result, 
many of the inhibitors/drugs are developed to regulate mSH function. 
4.2 Human Acetylcholinesterase: 
4.2.1 Function of Human Acetylcholinesterase: 
          Human acetylcholinesterase (hAChE) plays a major role in the signal transduction 
from one neuron to another one in the central nervous system (Rosenberry, 1975). The 
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Figure 4.1: Secondary Structure of the α/β Hydrolase Fold. The β-sheets are denoted 
as β, and α-helices are denoted as α. β-sheets are mostly parallel with exception of the 
second β-sheet. The nucleophile (Ser) is located between β5 and α5,6, the acid is located 
between β7 and α7,8, and highly conserved histidine is located between β8 and α1,8. 
Adapted from (Lord et al., 2013). 
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Figure 4.2: Mechanism of Substrate Hydrolyzation by Serine Hydrolase. First step, 
the serine amino acid gets activated by an electron relay process. Then, the serine residue 
attacks the ester carbon of the substrate. As a result, substrate kicks off the ester (OR) 
tail. Second step, the hydroxyl oxygen attacks ester carbon of the substrate which leads to 
bond breaking between the serine residue oxygen and substrate. Then the serine residue is 
deactivated. 
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main function of hAChE is the hydrolysis of the neurotransmitter acetylcholine (ACh) in 
the synaptic cleft. The neurons of the nervous system have communication between each 
other through chemical synapses that involve the axon of the stimulating neuron and the 
dendrite of the receiving neuron. The transduction of the signal from one neuron to 
another one happens the following way: the action potential (electric signal) stimulates 
the uptake of Ca
2+ 
into the axon which leads to release of the neurotransmitter (ACh) into 
the synaptic cleft where it binds to the acetylcholine-gated ion channels of the dendrite 
(post-synaptic neuron) (Fig. 4.3). The activated Na
+
 channels change the electrochemical 
state inside of the dendrite. Whenever the concentration of the Na
+
 ions reaches the 
threshold, an action potential is generated. To stop the transmission of the signal, AChE 
hydrolyses AChE. Liberated choline molecules are up taken by pre-synaptic neuron 
where acetylcholine is regenerated. 
4.2.2 Structure of Human Acetylcholinesterase: 
  Human AChE is a 64 kDa protein and functional as a homotetramer. AChE 
adopts the α/β fold with the catalytic triad Ser203, Glu334, and His447 (Fig. 4.1). A 20 Å 
deep gorge is observed in the crystal structure of the human AChE with the catalytic triad 
4 Å above the bottom of the gorge (Fig. 4.4) (Kryger et al., 2000; Patocka et al., 2004; 
Zimmerman & Soreq, 2006).  
The gorge consists of the peripheral anionic site (PAS) nearby the entrance of the 
gorge, the catalytic triad, the hydrophobic region, and the oxyanion hole (Fig. 4.4). The 
PAS consists of 5 residues (Tyr72, Asp74, Tyr124, Trp286, and Tyr341) that are 
surrounded by 10 acidic residues (Felder et al., 1997). The critical PAS acidic residue is 
Asp74; it affects the conformation of the active site (gorge) and the PAS site 
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Figure 4.3: Neurotransmission. Action potential (1) activates Ca
2+
 channels (2) which 
leads to the neurotransmitter (ACh) release into the synaptic cleft (3). ACh activates 
ligand-gated ion channels (4) resulting in a change of the membrane potential (5). To stop 
the signal transmission, most of the ACh is degraded by AChE, some is taken up by 
axon, and some diffuses away (6). Adapted from (Bear, February 25, 2014). 
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Figure 4.4: Structure of the Recombinant Human AChE Gorge. The figure shows the 
peripheral site outside the gorge and active site inside the gorge of AChE. (A) Cartoon 
representation of the peripheral binding site and active site gorge of AChE. Adapted from 
(Singh et al., 2013) (B) The peripheral site residues are shown in orange/yellow. The 
active site catalytic triad (Ser203-Glu334-His447) is shown in red. The oxyanion hole 
residues are shown in purple. The active site conserved Trp86 residue is shown in green. 
The raw sequence was downloaded from Protein Data Bank and modified using 
SwissPDB Viewer.          
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(Mallender et al., 2000). The hydrophobic region is responsible for binding the substrate. 
The oxyanion hole consists of Ala 204, Gly121, and Gly122, all of which stabilize the 
substrate in its intermediate state (Fig. 4.2) (Sussman et al., 1991; Ordentlich et al., 
1993).   
4.3 Inhibitors of Acetylcholinesterase: 
 AChE is a drug target enzyme in the treatment of Alzheimer’s disease (AD), 
glaucoma, neuromuscular blockage in surgical anesthesia and myasthenia gravis 
(Blichfeldt-Lauridsen & Hansen, 2012). AChE plays couple of roles in AD: its activity 
leads to decreased levels of ACh in the brain. In AD, low levels of ACh make signal 
transduction problematic. Therefore, it was proposed to inhibit AChE in AD patients. The 
second role of AChE in the AD is formation of the complex with β-amyloid via 
interaction of AChE peripheral site with β-amyloid. These complexes are more toxic than 
the aggregates of β-amyloid by itself (Alvarez et al., 1997; Alvarez et al., 1998). The best 
AChE inhibitors for treatment of AD should bind the PAS and active site of AChE. 
4.3.1 Reversible Inhibitors: 
 There are at least four different reversible laboratory-synthesized and 
natural inhibitors of AChE that are commercially available: Tacrine (1993), Donepezil 
(1996), Rivastigmine (2000), and Galantamine (2001) (Table 4.1). Other inhibitors that 
have been studied include: physostigmine, huperzine, and neostigmine (Table 4.1). 
Tacrine, Rivastigmine and Galantamine interact with the AChE active site, while 
Donepezil interacts with the active site, gorge aromatic residues, and the PAS of the 
AChE. Donepezil is the only one that exhibits the dual binding site mode. Most of the 
discussed inhibitors have IC50’s in the low nM range, while Rivastigmine and  
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Table 4.1: Reversible Commercially Available Inhibitors of Human AChE. 
a
(Bolognesi et al., 2007); 
b
(Hostettmann, 2006). 
 
 
 
 
Name Structure IC50 [nM]  
 
 
Tacrine 
 
 
 
424
a 
 
 
Synthetic  
 
 
Donepezil 
 
 
 
 
23
a 
 
 
Synthetic 
 
 
Rivastigmine 
 
 
 
3030
a 
 
 
Synthetic 
 
 
Galantamine 
 
 
 
 
2010
a 
 
 
Natural 
 
 
Physostigmine 
 
 
 
 
251
b 
 
 
Natural 
 
 
Neostigmine 
 
 
 
 
2 
 
 
 
Synthetic 
 
 
Huperzine A 
 
 
 
 
82
b 
 
 
Natural 
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Galantamine have low μM range IC50’s (Hostettmann, 2006; Bolognesi et al., 2007). All 
of these inhibitors form the complex through cation-π or π-π interactions with aromatic 
residues of the gorge that stabilize the substrate ACh through the same interactions for 
hydrolysis (Harel et al., 1993).  
4.3.2 Irreversible Inhibitors of AChE - Organophosphates: 
Many of organophosphates are irreversible inhibitors of AChE. The inactivation 
of the AChE leads to seizures and the failures of the cardiovascular, central nervous, 
respiratory systems (Solberg & Belkin, 1997). Organophosphates like DIFP, Tabun, 
Saring GB, Soman GD, Cyclosarin GF, and VX were developed as nerve agents during 
WWII and were extensively used in inhibitory studies of AChE (Fig. 4.5). It is known 
that organophosphates inhibit AChE by covalently modifying the active site Ser203. 
Complexes of the inhibitors with Ser203 are irreversible (covalent), but can be 
reversed by action of the antidotes that include atropine, scopolamine, pralidoxime 
chloride, and anticonvulsant medications (Bozeman et al., 2002). 
The main utilization of organophosphates since WWII has been in agriculture, 
where they were used as pesticides (Singh et al., 2013). In the mid-1980s, when there was 
more known about Alzheimer’s disease, organophosphates were used as a treatment for 
AD conditions (Singh et al., 2013). 
4.4 Hormone Sensitive Lipase: 
4.4.1 Function of Hormone Sensitive Lipase:  
Hormone sensitive lipase (HSL) plays a major role in lipolysis. HSL hydrolyses 
triacylglycerol (TAG), diacylglycerol (DAG), monoacylglycerol (MAG) (Fig. 4.6) 
(Stralfors, 1987; Lass et al., 2011), cholesteryl esters (Fredrikson et al., 1981), steroid 
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a.)                                     b.)                                              c.) 
 
           d.)                               e.)                                                           f.) 
Figure 4.5: Stuctures and Names of the Organophosphate Inhibitors of AChE. a.) 
Diisopropylfluorophosphate (DIFP), b.) Tabun (N,N-dimethylethyl 
phosphoramldocyanidate), c.) Sarin GB (O-isopropyl methylphophonofluoridate), d.) 
Soman GD (3,3-dimethyl-2-butyl methylphosphonofluoridate), e.) Cyclosarin GF (O-
cyclohexyl methylphosphofluoridate), f.) VX (O-ethyl S-diisopropylaminoethylmethyl 
phosphothioate). 
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Figure 4.6: Hydrolysis of the TAG to Glycerol and FFAs. Adopted from (Lampidonis 
et al., 2011). 
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fatty acid esters (Lee et al., 1988), retinyl esters (Wei et al., 1997), and para-nitrophenyl 
esters (Osterlund et al., 1996). Hormone sensitive lipase has a greater preference 
forcholesteryl esters, steroid fatty acid esters, retinyl esters, and para-nitrophenyl esters 
than for TAG, DAG, and MAG. HSL substrate preference is DAG>TAG>MAG 
(Fredrikson & Belfrage, 1983; Rodriguez et al., 2010). HSL distinguishes between 
different DAGs: it hydrolyses 1,3-acylglycerol 3-4-fold times faster than 1,2-acylglycerol 
(Fredrikson & Belfrage, 1983).  
4.4.1.1 HSL Activation: 
 HSL activation starts with hormones (glucagon) and neurotransmitters 
(norepinephrine) binding to the receptors in the cell membrane (Fig. 4.7). G-proteins that 
are associated with the glucagon/adrenergic receptors are activated, which, as a result, 
activate adenylate cyclase. Adenylate cyclase produces cAMP, elevated levels of which 
activate phosphokinase A (PKA) (Steinberg & Huttunen, 1972). PKA then 
phosphorylates Perilipin-1 and HSL (Ser563, Ser 659 and Ser660) (Holm et al., 2000). 
HSL, upon activation, translocates from the cytosol to the lipid droplet where it 
hydrolysis DAG (Brasaemle et al., 2000). 
Insulin, upon binding to the cell membrane receptor, activates the phosphokinase 
B (Akt) signaling pathway which activates phosphodiesterase 3B (PDE3B). The main 
role of PDE3B is the hydrolysis of the cAMP. Lower levels of cAMP deactivate the PKA 
dependant signaling pathway deactivating HSL lipid hydrolysis (Holm et al., 1997). 
4.4.2 Structure of Hormone Sensitive Lipase: 
 HSL is a 84,073 kDa protein, and its active form is a homodimer. HSL has a 
catalytic triad of Ser423-Asp703-His733 (Holm et al., 1988a; Holm et al., 1994)  
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Figure 4.7: Lipolysis and Role of HSL in it. Activated adrenergic receptor, through 
elevated levels of cAMP, activates PKA. PKA phosphorylates/activates HSL which 
promotes HSL translocation to the lipid droplet. PKA phosphorylates Perilipin-1 as well. 
Phosphorylated Perilipin-1 leaves the lipid droplet and liberates CGI-58 (activator of 
Adipose Triglyceride Lipase - ATGL). ATGL hydrolyzes TAG to DAG, HSL hydrolyzes 
DAG to MAG, and MGL hydrolyzes MAG to glycerol and FFA. Receptor Bound insulin 
activates PKB. PHB activates PDE3B, which hydrolyzes cAMP, deactivating PKA. 
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(Shen et al., 2000). HSL adopts the α/β fold, as do many other SH, but it has a regulatory 
motif incorporated in between β6 and β7 β-sheets (Contreras et al., 1996). 
 HSL consists of 4 domains: the N-terminal, the carboxyl-terminal, the regulatory, 
and the putative lipid-binding domain. The structure of the N-terminal domain (amino 
acids 1-300) is unknown. It is proposed that the N-terminal domain functions in the 
dimerization of HSL as well as in the interaction with fatty acid binding protein (FABP). 
For FABP to bind HSL, HSL has to be activated/phosphorylated and ready for lipolysis. 
The binding of FABP to HSL enhances lipolysis 3-fold (Smith et al., 2007). The 
carboxyl-terminal domain includes the regulatory domain and the catalytic triad 
(Contreras et al., 1996; Zimmerman & Soreq, 2006). The carboxyl-terminal domain 
(amino acids 300-768) folds into the α/β fold with 7 β-sheets and 8 α-helices. The 
regulatory module consists of amino acids 521-669 and contains 5 phosphorylation sites 
(Ser563, Ser565, Ser 600, Ser659, and Ser660). The putative lipid binding domain 
corresponds to residues 658-768 in HSL (Smith et al., 1996). This domain has a 
hydrophobic patch, residues 734-741 (FLSLAALC), that is involved in conformational 
changes (Smith et al., 1996) (Holm et al., 1988b) (Krintel et al., 2009). This 
conformational change results in a hydrophobic surface exposure in HSL upon 
phosphorylation (Krintel et al., 2009).   
Partial proteolysis of HSL shows that HSL loses its catalytic activity towards 
trioleoyl glycerol and other long chained DAGs upon cleavage while activity towards the 
short chained esters (p-nitrophenyl butyrate) is still present. Brefeldin A esterase has a 
Tyr residue that forms part of the substrate binding pocket at the position where HSL has 
an Ala; mutation of the Ala to Phe in HSL abolishes hydrolysis of substrates with long 
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chains (Wei et al., 1998). In conclusion, HSL has an acyl-binding site that is mainly 
formed by the regulatory domain.       
4.5 Inhibitors of Hormone Sensitive Lipase:  
There are two types of diabetes: type I, where insulin is not produced but all of 
the signaling pathways work, and type II, where insulin is produced but signaling 
pathways are impaired (Gonzalez-Sanchez & Serrano-Rios, 2007).  Most diabetes 
patients (90-95%) have type II diabetes. Under type II diabetes conditions, HSL is always 
activated, and as a result, an increased hydrolysis of TAG is observed. Products of TAG 
hydrolysis (FFA and glycerol) are released into the blood stream, hindering glucose 
utilization leading to hyperglycemia. Products of HSL hydrolysis are related to the 
development of insulin resistance (Jianping, 2007). It was proposed that inhibition of 
HSL in diabetes patients will minimize the hydrolysis of TAG and lower the 
concentration of glucose in the blood as a result (Claus et al., 2005). 
There are several classes of reversible and irreversible inhibitors of HSL reported 
in the literature (Table 4.2) (Slee et al., 2003; de Jong et al., 2004; Ebdrup et al., 2004; 
Lowe et al., 2004; Ebdrup et al., 2005; Ben Ali et al., 2006; Ebdrup et al., 2007). Most of 
the inhibitors were tested only in vitro. All of the inhibitors are synthetic, and some were 
found using high-throughput screening against HSL. There is no data that would show 
that the HSL active site is bound by inhibitors of any of these classes; therefore there is 
no data about which of the HSL active site amino acids are involved in inhibitor-enzyme 
interactions.  
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Table 4.2: Classes of HSL Inhibitors. 
Class of Compound Structure IC50 (nM) 
Lipase Assay 
Oxadiazolone 
a
  
 
60 
2H-isoxazol-5-ones
 b 
 
1 
 
Carbomoyltriazole 
c 
 
20 
Carbazate 
d 
 
3 
Pyrrolopyrazinedione 
e 
 
180 
Boronic Acid 
f 
 
17 
Carbamate 
g 
 
23 
a
(Ben Ali et al., 2006); 
b
(Lowe et al., 2004); 
c
(Ebdrup et al., 2004); 
d
(de Jong et al., 2004); 
e
(Slee et al., 2003); 
f
(Ebdrup et al., 2005); 
g
(Ebdrup et al., 2007). 
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Recently, classes of natural product organophosphates were found to be inhibitors 
of AChE and HSL (Kurokawa et al., 1993; Vertesy et al., 2002; Dutta et al., 2010b). 
These will be discussed in Chapter VI. 
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CHAPTER V 
MATERIALS AND METHODS 
5.1 The Effect of Organophosphates on Serine Hydrolases: 
Human acetylcholinesterase, acetylthiocholine, and 5,5’-dithiobis-2-nitrobenzoic 
acid (DTNB) were purchased from Sigma Co, Saint Louis, MO. All cyclophostin and 
cyclipostin derivatives were supplied by the Dr. Spilling Lab at the University of 
Missouri, Saint Louis, MO. 
5.2 The Effect of Organophosphates on Human Acetylcholinesterase (AChE): 
5.2.1 Acetylcholinesterase Assay:  
 Human acetylcholinesterase (AChE) was quantitated by ultraviolet-visible 
spectrophotometer (UV-Vis) using 119,656 M
-1
cm
-1
 as the extinction coefficient at 280 
nm (Pace et al., 1995). Human AChE powder was dissolved in 100 mM Tris buffer, pH 
8.0, at 25
o
C and supplemented with 1% bovine serum albumin (BSA). Human AChE was 
assayed using Ellman’s protocol (Ellman et al., 1961). Acetylcholinesterase hydrolyzed 
acetylthiocholine to acetic acid and thiocholine; the latter reacted with DTNB (5,5’-
dithiobis-2-nitrobenzoic acid), which produced a thionitrobenzoate anion which absorbed 
light at 412 nm. Enzyme specific activity varied from day to day; the general guideline 
was to use enough enzyme to produce an average of 200 mAbs/sec in the assay. The 
quantity of enzyme in the assay that produces the curve for IC50 determination was held 
constant for each session. The enzyme was assayed using 500 μM acetylthiocholine 
(ATCh) as the substrate and 0.3 mM DTNB with a final volume of 1106 μL. The 
substrate concentration used for inhibitory work was above the human AChE Km of 46 
μM (Radic et al., 1993). 75 mM ATCh stock was prepared in water; 10 mM DTNB was 
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prepared in 100 mM Tris buffer pH 7.0 (vigorous vortexing); 100 mM Tris buffer pH 8.0 
was used. The reaction was continuously mixed by a micro spinner placed in the cuvette 
(Fisher; Cat. No. NC9028779).  The reaction progress was monitored through 60 sec, and 
60 data points were acquired with a Shimadzu Scientific UV-Vis Spectrophotometer 
1800. Only 20 absorbance points were used to determine the initial velocity of the 
reaction in mAbs/sec.  
5.2.2 Test of IC50s for Cyclophostin Derivatives with AChE: 
 The cyclophostin derivatives were dissolved in isopropanol. The concentration of 
isopropanol in the reaction with the enzyme never exceeded 5%. Human AChE was 
preincubated with increasing concentrations of inhibitor in 100 mM Tris, pH 8.0, 
supplemented with 1% BSA (bovine serum albumin). Inhibitor concentration was held 
constant between the preincubation solution and the reaction solution; therefore, some 
inhibitor was added to the reaction pot of 1106 μL. The residual activity of the AChE was 
measured by Ellman’s assay as described above. The percent residual activity was plotted 
as a function of inhibitor concentration. The concentration of inhibitor at 50 % residual 
activity of the enzyme was determined as the IC50. 
 The fluorinated cyclic phosphonate (Table 6.4) compound was unstable at pH 
8.0, the pH that the assay was run at. Therefore, the stability studies were performed by 
Ben Martin using NMR. In this study, it was concluded that this compound was stable at 
pH 6.0; therefore, the acetylcholinesterase assay was performed using 50 mM MES pH 
6.0 in addition to 100 mM Tris pH 8.0. Nonfluorinated compounds were examined at pH 
6.0 for relevant comparison reasons. The activity of the human AChE at pH 6.0 is 80% of 
that at pH 8.0 (Skaer, R. J., 1973). 
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 5.3 Effect of Organophosphates on Recombinant Rat Hormone Sensitive Lipase 
(HSL): 
5.3.1 Cell Culture: 
 SF9 cells were grown in a monolayer inside T-150 flasks (Fisher) at 27
o
C without 
CO2. A growth medium consisting of TNM-FH medium, 10 % heat inactivated FBS, 100 
units/ ml penicillin G, and 100 μg/ml streptomycin was supplemented to the SF9 cells. 
The SF9 cells were subcultured 3-7.5 e6 cells/ T-150 flask (2-5 e4 cells/ cm
2
) whenever 
cells reached 90% confluency.  
5.3.2 Protein Production: 
 The gene for rat hormone sensitive lipase was a generous gift from Dr. F.B. 
Kraemer’s lab from Stanford University. Cloning and DNA production were performed 
by Supratik Dutta (Dutta, 2010a). 
  Trasfection of the pAcHLT-A-HSL DNA was performed using the BaculoGold 
Transfection kit (BD Biosciences; Cat. No. 560129). Recombinant virus DNA consisted 
of pAcHLT-A-HSL and linearized AcNPV Baculovirus DNA. pAcHLT-A-HSL and 
linearized AcNPV Baculovirus DNA were co-transfected into SF9 cells using the Ca
II
- 
phosphate precipitation method (BD Biosciences; Cat. No. 560129).  Recombination 
between pAcHLT-A-HSL and baculovirus DNA occurred in SF9 cells.  Successful 
expression of the HSL gene was confirmed by Western blot on the virus-infected cell 
lysate 72 hours after cells were transfected. The Western blot was performed using an 
anti-rabbit HSL polyclonal antibody (Cayman Chemical; Cat. No.10006371) or 6X-His 
tag antibody (Cell Signaling; Cat. No. 2365S) as the primary antibodies and anti-rabbit 
horseradish peroxidase antibody as the secondary antibody. 
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 For high titer rat HSL baculovirus production, transfected SF9 cells were left to 
grow for 144 hours (6 days). During that time, recombinant baculovirus was produced 
from SF9 cells. The media from transfected SF9 cells was collected and sent to Allele 
Biotechnology for virus amplification. The high titer virus received from the company 
was ~ 1 e8 pfu/ml.  
 For protein production, 4 e7 SF9 cells in T-150 flasks (Fisher) (70% confluent) 
were infected with recombinant baculovirus at 8 m.o.i. (multiplicity of infection - virus-
to-cell ratio). SF9 cells were collected 72 hour post infection and centrifuged at 1,500g 
for 20 minutes. Then, small pellets were combined into one pellet and were centrifuged 
another 15 minutes. The pellet was stored in a -80
o
C freezer.  Because HSL is not a 
secreted protein, only cells were collected, and the supernatant was discarded. 
5.3.3 Protein Purification: 
 The homogenization buffer contained 75 mM Tris, 10% glycerol, 1 mM DTT and 
1% C13E12 (poly (ethylene glycol)(12) tridecyl) (Sigma, Cat. No. 466417), pH 8.0 at 4
o
C. 
The homogenation buffer was supplemented with a protease inhibitor cocktail for a final 
concentration of 0.2 μM bestatin hydrochloride, 0.01 μM E-64, and 10 μM 
phosphoramidon disodium salt. This mixture of homogenation buffer with the protease 
inhibitor cocktail was added to the SF9 cell pellet containing HSL in a ratio of 15 mL of 
buffer per gram of SF9 cell pellet. The pellet was homogenized by stirring. The 
homogenized cell solution was sonicated using a Branson Sonifier 250 sonicator for 2 
minutes on setting 2, then for 2 minutes on setting 4 with 30 sec intervals on ice between 
each minute of sonication. The sonicated solution was centrifuged at 11,000g at 4
o
C for 
30 min. Meanwhile, Ni-NTA beads (Qiagen; Cat. No. 30410) were equilibrated with the 
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homogenation buffer 3 times for 5 minutes and spun down at 13,000g for 1 min after 
each incubation. The pH of the supernatant containing 6X-His tag rat HSL was confirmed 
(pH 8.0) followed by incubation with Ni-NTA beads for 1.5 hours at 4
o
C.  
The Ni-NTA beads with rat HSL bound were washed twice with 1 mL of elution 
buffer containing 75 mM Tris, 0.3 M NaCl, 1 mM DTT, 10 % glycerol, 0.01 % C8E4 
(tetrathylene glycol monooctyl ether) (Sigma, Cat. No. T3394), pH 8.0, to wash away 
nonspecifically bound proteins. Next, HSL bound Ni-NTA beads were incubated for 5 
min with 300 μL of elution buffer with increasing amounts of imidazole (5-400 mM), and 
the flow through was collected in 300 μL fractions. 
10% SDS PAGE was performed to evaluate the efficiency and outcome of rat 
HSL purification from SF9 cells (Fig. 5.1). The most concentrated and most pure 
fractions were combined and were dialyzed using Slide-A-lyzers (Pierce) against  1 L of 
elution buffer without imidazole. The concentration of recombinant rat HSL was 
measured using a UV-1800 spectrophotometer (Shimadzu) at 280 nm with an extinction 
coefficient of 52,090 M
-1 
cm
-1
 (Pace et al., 1995).  
5.3.4 HSL Lipase Assay:  
The HSL lipase assay was based on the principle that the enzyme hydrolyzes 
triacylglycerol to glycerol and fatty acids (Fredrikson et al., 1981). In this assay, HSL 
hydrolyzes 9, 10 – 3H triolein to glycerol and oleic acid (Fig. 5.2). Triolein is delivered to 
HSL as a part of liposomes. The liposomes consisted of 200 μM phosphatidylcholine and 
phosphatidylinositol (3:1 w/w), 500 μM cold triolein, and 120 μL of 3H triolein (0.06 
mCi) per 20 mL (Fredrikson et al., 1981). All of these components were in chloroform; 
therefore, they were dried under a vacuum before adding the lipase assay buffer (25 mM  
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Figure 5.1: 10% SDS PAGE Gel of Recombinant Rat HSL Purification from SF9 
Cells Using Ni-NTA Beads. Analysis of HSL fractions. An imidazole gradient between 
5 and 400 mM was used to elute Ni-NTA beads bound to the 6x-His tag rat HSL.  The 
SDS gel shows the amount and purity of rat HSL in each imidazole fraction. Lane 1 is the 
prestained protein marker (NEB, Cat. No. P7708S); lanes 2, 3, 4, 5 are rat HSL elutions 
at 200, 250, 350, and 400 mM imidazole solutions respectively.  Purified, recombinant rat 
HSL can be seen at the 84 kDa molecular weight mark.   
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Figure 5.2: Hydrolysis of 
3
H Labeled Triolein by HSL. (A) HSL hydrolysis of triolein 
into oleic acid and glycerol. The reaction was stopped by the addition of the stop buffer 
(aqueous layer: 50 mM K2CO3, 50 mM K3BO3, and 50 mM KOH). Oleic acid was 
extracted by the addition of the organic layer (1.41: 1.25: 1 v/v MeOH, CHCl3, C7H16). 
(B) When stop buffer and the 1
st
 organic layer were added to the reaction mixture, the 
product (oleic acid) of the lipase assay migrated into the top (aqueous) layer due to 
charge, while triolein migrated into the organic layer, due to its lipophilicity. After 
centrifugation, the top (aqueous) layer was transferred to a new tube with a new mixture 
of the stop buffer and the 2
nd
 organic layer. Oleic acid separated into the aqueous layer 
while the triolein that was not extracted in the first extraction was separated into organic 
layer during the second extraction. After centrifugation, the aqueous layer was extracted 
for counting.   
HSL 
Transfer top 
(aqueous layer) 
Mix        
Centrifuge 
 
Transfer top 
(aqueous layer) 
A 
B 
1
st
 organic 
layer 
2
nd
 organic 
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Tris, pH 7.4, 150 mM NaCl, 0.2 mM EDTA, and 1 mM β- ME (2- mercaptoethanol)). 
After addition of the lipase assay buffer, sonication was required because the formation 
of liposomes is unfavorable. Sonication (Branson sonifier) was performed on ice as 
follows: 2 min on setting 2 and 2 minutes on setting 4 with a 30 second pause between 
each minute. The concentration of cold triolein in the substrate with the HSL reaction 
was 400 μM. 0.2 % BSA was added to the reaction. Before the addition of HSL to the 
reaction, the reaction mixture was warmed to 37
o
C. 
The volume of the reaction was calculated depending on how many points were 
required to obtain the best result. The amount of HSL that had to be used was the amount 
enough to obtain a rate of 20-40 CPM/min which was ~20-80 nM, depending on the HSL 
prep. The reaction was monitored for 30 min at 37
o
C. For IC50 studies, points were taken 
every 10 minutes; while for kinetic studies, points were taken every 5 minutes. 
HSL activity was monitored by the withdrawal of 120 μL of reaction mixture per 
time point. The reaction was stopped, and radioactively labeled oleic acid was extracted 
by the addition of 50 μL of the stop buffer (50 mM potassium carbonate- potassium 
borate- potassium hydroxide buffer at pH 10) and 100 μL of the organic layer consisting 
of methanol: chloroform: heptanes (1.41: 1.25:1, v/v). The resulting mixture of HSL 
reaction solution, stop buffer, and organic layer was vortexed and centrifuged at 13,000 
rpm for 4-5 minutes. Then, 140 μL of the top (aqueous) layer was removed and added to 
a second mixture of fresh stop buffer and a fresh organic layer for a second extraction. 
After the second extraction was performed, 160 μL of the aqueous layer was placed in a 5 
mL scintillation vial with 3 mL of scintillation fluid.  
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Figure 5.3: Activity of Rat HSL Measured by 
3
H-Oleic Acid Release. 20 nM rat HSL 
was incubated with 400 μM 3H-triolein delivered in 200 μM PC/PI (3:1 w/w) liposomes 
for 30 min at 37
o
C.
 
Every ten minutes, a 120 μL aliquot was extracted and analyzed. 
Counts per minute (CPM) were determined and plotted vs time. The plot was fit to a line 
with the slope representing the reaction rate.  
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The radioactivity was counted by liquid scintillation counting. The rates were 
calculated by plotting cpm vs. time (Fig. 5.3).  
5.3.5 IC50s of Cyclipostin and Its Derivatives on Rat HSL: 
 Because these compounds are insoluble in water, they were delivered to HSL as a 
part of liposomes. The liposomes consisted and were prepared the same way as liposomes 
with substrate. Each stock concentration of inhibitor was prepared separately. During the 
assay, the PC/PI concentration was always 200 μM during the preincubation (compound 
with HSL) and in the reaction of HSL with substrate. 
To test cyclipostin derivatives on rat HSL, varying concentrations of inhibitor 
were first preincubated with enzyme on ice for 30 min and then tested for residual 
activity. The inhibitor concentration was kept constant in the preincubation and assay 
mixture. Each IC50 experiment was performed at least three times. 
5.3.6 Kinetic Analysis of Cyclipostin P Trans on Rat HSL: 
 For the kinetic analysis of cyclipostin P Trans, the inhibitor was not preincubated 
with the enzyme alone for 30 minutes as for IC50s determination. The inhibitor was added 
to enzyme at the same time as the substrate for the enzyme. The concentration of the 
enzyme was also higher (~100 nM) than in IC50s determinations because, for the kinetic 
evaluation of the compound, saturation of the enzyme with substrate (Vmax) had to be 
reached.  
The kinetic analysis of cyclipostin P Trans on rat HSL was performed to 
determine the binding equilibrium constant (KI), forward rate inactivation constant (k2) 
and reverse rate inactivation constant (k-2). 
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The interaction of Trans cyclipostin P and HSL could be described by two- steps 
(Model 5.1):                    
                      KI             k2 
                                              E+I         EI         EI* 
    k-2 
Model 5.1:  E = Enzyme, I = Inhibitor, EI = Enzyme-inhibitor complex, EI* = 
Inactivated enzyme- inhibitor complex, KI = inhibition equilibrium constant, k2 = forward 
inactivation rate constant, and k-2 = reverse inactivation rate constant (Callan et al., 
1996). 
  
Eqn. 1 describes a mono-exponential decay where At is the remaining residual 
activity at any given time point after the reaction is started, A0 is the enzyme activity at 
the beginning of the reaction (time zero) in the absence of inhibitor, kobs is observed rate 
for the loss of activity.  
                                       At = A0 [(1-k-2 / kobs) * e^ (-kobs t) + k-2 / kobs]            Eqn.1. 
The residual activity of the enzyme was plotted as a function of reaction time for 
each inhibitor concentration. This data was fit to Eqn. 1 to obtain k-2 and kobs (Fig. 5.4).  
With a test reaction, k-2 was determined to be close to zero, which means that cyclipostin 
P Trans is an irreversible inhibitor of rat HSL.  
Therefore, to obtain the inhibition equilibrium constant, the data was fitted to the 
simplified Eqn.2: 
kobs = k2 * [I] / (KI+[I])        Eqn.2. 
Reaction time points for the kinetic analysis of cyclipostin P Trans with HSL  
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Figure 5.4: Determination of Reverse Inactivation Rate Constant. The residual 
activity % vs. time [min] was fitted to Eqn. 1: At = A0 [(1-k-2 / kobs) * e^ (-kobs t) + k-2 / 
kobs] to get the parameter k-2. k-2 is close to zero; therefore, the cyclipostin P Trans is an 
irreversible inhibitor and kobs = k2 * [I] / (KI+[I]) + k-2 can be simplified to the Eqn. 2. The 
inhibitor (cyclipostin P Trans) was not preincubated but instead was added to the enzyme 
at the same time as the enzyme’s substrate.          
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were obtained as discussed in the Materials and Methods Chapter 5.3.5 with the 
exception that HSL was not preincubated with the inhibitor on ice but instead added 
directly to the substrate-inhibitor mixture to start the reaction. The amount of HSL that 
was used had to be enough to observe the Vmax of the reaction, about 100 nM HSL. 
Aliquots were taken 3 minutes after the reaction began and every 5 minutes for 30 min at 
37
o
C. 
It was determined that as the concentration of inhibitor increased, the difference 
in counts between the zero time point and the thirty minute time point decreased. This 
corresponds to the concentration of extracted free fatty acid. This observation was used to 
plot the difference in counts at 0 and 30 min vs. concentration of inhibitor. This data was 
fit to Eqn. 2 to determine the inhibition KI and k2. 
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CHAPTER VI 
INHIBITION STUDIES OF HUMAN ACETYLCHOLINESTERASE 
AND RAT HORMONE SENSITIVE LIPASE BY 
ORGANOPHOSPHATES.  
6.1 Inhibition of Serine Hydrolases in the Presence of the Cyclophostin and 
Cyclipostin Derivatives:  
6.1.1 Natural Products - Cyclophostins: 
There are two classes of the organophosphates natural products (cyclophostin and 
cyclipostin) discovered that inhibit serine hydrolases. Cyclophostin is active against 
AChE, while cyclipostin is active against HSL.  
Cyclophostin/cyclipostin consists of a seven-membered phosphate ring and a five-
membered lactone ring fused together. The difference between cyclophostin and 
cyclipostin is that cyclophostin has a methyl at phosphate moiety, while cyclipostin has a 
long alkyl chain at phosphate moiety. There are two chiral centers in 
cyclophostin/cyclipostin: one at the phosphate moiety and the other at the hydrogen atom 
between the two rings (Fig. 6.1). Considering both chiral centers, 
cyclophostin/cyclipostin exists as two diastereomers, Cis and Trans. The carbon chain of 
the phosphate moiety and the hydrogen atom between the rings can lie on the same side 
of the seven-membered ring to form the Cis isomer or on opposite sides of the seven-
membered ring to form the Trans isomer. The natural product cyclophostin has a Cis 
conformation. The Trans diastereomer is an unnatural diastereomer of cyclophostin. 
Cyclophostin was extracted from Streptomyces lavendulae strain NK901093 
(Table 6.1) (Kurokawa et al., 1993). It was tested against housefly and brown  
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  Cis Diastereomer   Trans Diastereomer 
Figure 6.1: Cis and Trans Diastereomer of Cyclophostin. The Cis diastereomer (blue 
bonds) of cyclophostin is characterized by a carbon tail on the phosphate moiety and the 
hydrogen atom of the carbon that is between the rings on the same side of the seven-
membered ring. The Trans diastereomer (red bonds) of the cyclophostin is characterized 
by the carbon tail and the hydrogen atom being on the opposite sides of the seven-
membered ring. R’ represents alkyl chain of length between C1-C16. 
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Table 6.1: Structure of Inhibitors of Human Acetylcholinesterase Used in the Study 
of (Kurokawa et al., 1993). 
Adapted from (Kurokawa et al., 1993). 
 
 
 
 
 
 
 
 
 
 
 
Compound Structure Housefly 
AChE 
IC50 [μM] 
Brown 
planthopper 
AChE  
IC50 [μM] 
Propaphos 
 
6.2 0.96 
 
Physostigmine 
Sulphate 
 
 
5.0e-2 9.1e-2 
Cyclophostin 
 
7.6e-4 1.3e-3 
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planthopper AChE and compared to another two natural products, propaphos and 
physostigmine sulfate (Table 6.1). Cyclophostin showed at least a 60x stronger inhibitory 
effect than the other two natural compounds on both types of AChE (Table 6.1). 
Cyclophostin was synthesized in the lab and tested against housefly AChE. It 
demonstrated the same inhibitory effect as extracted cyclophostin with an IC50 of 0.76 
nM (Dutta et al., 2010b). The inhibitory effect of cyclophostin synthesized in the lab 
against human AChE was fifty times less pronounced than the effect on housefly and 
brown planthopper AChE. 
The natural and unnatural cyclophostin that were studied against human AChE 
showed that human AChE did not distinguish between Cis and Trans cyclophostin (Table 
6.2). The change of the phosphate to a phosphonate moiety (2a,b) in the seven-membered 
ring drastically decreased the inhibitory effect of the cyclophostin derivatives (75-750 
fold). The inhibitory effect of cyclipostin derivatives on human AChE did not change 
upon opening the lactone ring (monocyclic) (3a,b; 9) (Table 6.2),  but the 
stereoselectivity changed from the Trans diastereomer (2a) towards the Cis diastereomer 
(3b). 
 It was also shown by mass spectrometry that cyclophostin inhibits human AChE 
irreversibly, modifying catalytic amino acid Ser203 (Dutta et al., 2010b).    
 In conclusion, the cyclophostin family is a new class of the phosphate containing 
natural products which inhibit human AChE irreversibly.  
 In this study, the effect of the lactone ring in the phosphate analog and effect of 
the electron density on the phosphate moiety on the inhibitory effect of the cyclophostin 
derivatives against human AChE was investigated.   
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Table 6.2: Previously Studied Organophosphates and Organophosphonates against 
Human AChE.
a 
a
(Bandyopadhyay et al., 2008) (Dutta et al., 2010b) (Malla et al., 2011). 
 
 
 
 
 
Compound Structure Diastereomer Human AChE 
IC50 [μM] 
 
 
DIFP
 
 
 
 
 
 
N.A. 
 
 
0.12 
 
Natural 
Cyclophostin 
  
 
Cis 
 
0.04 
 
Unnatural 
Cyclophostin 
  
 
Trans 
 
0.035 
 
2b 
 
 
Cis 
 
30 
 
2a 
 
 
 
Trans 
 
3 
 
3b 
 
 
 
Cis 
 
~6 
 
3a 
 
 
 
Trans 
 
~35 
 
9 
 
 
 
N.A. 
 
7 
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6.1.2 Natural Products - Cyclipostins: 
Cyclipostins are natural product inhibitors of HSL described by Vertesy (Table 
6.3) (Vertesy et al., 2002). Cyclipostin derivatives were isolated from Streptomyces 
species strain DSM 13381 (Vertesy et al., 2002). Derivatives of cyclipostin were tested in 
vivo and in vitro on HSL from adipose tissue. The IC50s that were obtained were in the 
nanomolar range in vivo and the in vitro, suggesting that cyclipostin derivatives can be 
easily transported across the cell membrane (Table 6.3) (Vertesy et al., 2002). From 
previous studies of irreversible cyclophostin derivatives with acetylcholinesterase, it was 
predicted that cyclipostin derivatives modify a serine residue in HSL active site (Dutta et 
al., 2010b). 
 In this study, the effects of the lactone ring, electron density of phosphate moiety, 
diastereomer preference, chain length, and position of the chain in the compound on the 
inhibitory effect of the cyclipostin derivatives against rat HSL were investigated. The 
inhibitory mode of the cyclipostin derivative was investigated against rat HSL as well.     
6.2 Human Acetylcholinesterase Inhibition and Structure-Activity Relationship of 
Cyclophostin Analogs: 
This study focused on altering the phosphate moiety reactivity of cyclophostin. 
The reactivity of the phosphate moiety was altered by making the phosphate more or less 
electron rich. If the oxygen in the seven-membered ring was substituted with carbon 
(phosphonate), this change made the phosphate more electron rich. The inhibitory effect 
of these compounds (4a,b) (Table 6.4) decreased drastically relative to cyclophostin. To 
decrease the electron density around the phosphate, two fluorine atoms were introduced 
close to the phosphate moiety (8) (Table 6.4). This modification eliminated the  
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Table 6.3: Inhibitory Studies of the Cyclipostins against HSL. 
Adapted from (Vertesy et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Core structure of 
Cyclipostin 
Analogs IC50 [nM] 
Name R’ R’’ In 
vitro 
In 
vivo 
 
A 
 
CH3(CH2)3 
CH(OH)(CH)11 
CH3 20  190  
P CH3(CH2)15 CH3 30  85  
P2 CH3CH(CH3)(CH)13 CH3 40  150 
S CH3(CH2)15 CH2CH3 20  40 
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Table 6.4: IC50s of Cyclophostin Derivatives against Human AChE. 
a
(Bandyopadhyay et al., 2008) (Dutta et al., 2010b) (Malla et al., 2011).  
N.A.- Not Applicable. N.D.- Not Determined.  
Compound Structure Diastereomer Human AChE 
IC50 [μM] 
pH=8 pH=6 
Natural 
Cyclophostin
a 
1a 
 
Cis 0.04 N.D. 
Unnatural 
Cyclophostin
a 
1b 
 
Trans 0.035 N.D. 
2 
 
N.A. 1.03±0.2 1.04±0.26 
3 
 
N.A. 5.9±0.2 6.1±1 
4a
a 
 
Cis 30 N.D. 
4b
a 
 
Trans 3 N.D. 
6
a 
 
N.A. 7; 17 26±4.0 
7 
 
N.A. 7.5±0.5 8.9±0.2 
8 
 
N.A. >100 >100 
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compound’s inhibitory effect on human AChE whenever the assay was performed at pH 
8.0 where fluorinated compound is not as stable. The fluorinated compound was re-
evaluated at pH 6.0, where it is stable, but the fluorinated compound still did not show 
any inhibitory effect against human AChE up to 100 μM, even though the compound was 
stable. 
When the lactone ring was removed and only methyl acetate was left (2), the 
inhibitory affect of the compound was reduced thirty fold relative to natural cyclophostin. 
If instead of the methyl acetate, t-butyl acetate (3) was present, the inhibitory effect was 
reduced 170 fold relative to natural cyclophostin (Table 6.4). 
The change in the inhibitory effect for phosphate to phosphonate derivatives for 
bicyclic compounds (1a,b; 4a,b) was affected from twelve to one hundred times more 
than for monocyclic cyclophostin derivatives (2; 3; 6; 7) (Table 6.4).  
The presence of the short chain of the phosphate moiety (methyl (6) or ethyl (7)) 
did not affect the IC50 towards human AChE (Table 6.4).     
6.3 SAR Studies with Laboratory Synthesized Organophosphates on Recombinant 
Rat Hormone Sensitive Lipase: 
 Table 6.5 shows all of the cyclophostin and cyclipostin derivatives that were 
tested against recombinant rat HSL using the lipase assay described in the Materials and 
Methods (Chapter 5.3.4).  
6.3.1.1 Cyclophostin vs. Cyclipostin Compounds: 
Cyclipostin, a natural product, and its phosphonate synthetic analog were not 
potent against HSL (IC50 > 100 μM), but the cyclipostin derivatives with the same core 
structure and a long carbon tail on the phosphate moiety were very potent. The most  
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Table 6.5: IC50 of Organophosphates and Organophosphonates against Rat HSL. 
Compound Structure Tail Diastereomer IC50 [μM] PC:PI 
Natural 
Cyclophostin 
1a  
1 Cis >100 3:1 
Synthetic  
Cyclophostin 
1b  
1 Trans >100 3:1 
Cyclophostin 
Phosphonate 
analog 6  
1 Trans 100  3:1 
Cyclipostin R 
2a 
  
15 Cis 0.075±0.025 3:1 
Cyclipostin R 
2b 
 
15 Trans 0.9±0.9 3:1 
Cyclipostin P 
3a 
  
16 Cis 0.42±0.16 3:1 
Cyclipostin P 
3b 
  
16 Trans 0.025±0.015 3:1 
Cyclipostin R 
Phosphonate 
4a  
15 Cis 0.47 ± 0.38 3:1 
Cyclipostin R 
Phosphonate 
4b  
15 Trans 0.45 ± 0.25 3:1 
Cyclipostin P 
Phosphonate 
5a  
16 Cis 0.36 ± 0.34 3:1 
Cyclipostin P 
Phosphonate 
5b  
16 Trans 6.9 ± 2.4 3:1 
10 
 
16 N.A. 0.06 ± 0.02 3:1 
25 
 
16 N.A. 
30
a,b 
0.54±0.4 
1:3
 a,b 
3:1 
8 
 
18 N.A. N.D. N.D. 
9 
 
16 N.A. >100 3:1 
Continued, next page. 
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Table 6.5: (continued). 
Compound Structure Tail Diastereomer IC50 [μM] PC:PI 
 
22b
a 
  
5 Cis 100 
1:3
b 
1:2
b
 
 
22a
a
 
  
5 Trans 100 
1:3
b
 
1:2
b
 
 
23b
a
 
 
10 Cis 
400 
300 
40 
1:3
a,b
 
1:2
a,b 
3:1 
 
23a
a
 
  
10 Trans 
150 
100 
1:3
b
 
1:2
b
 
 
24b
a
 
  
12 Cis 
80 
50 
35 
1:3
a,b
 
1:2
a,b 
3:1 
 
24a
a
 
  
12 Trans 
350 
175 
13.5 
1:3
a,b
 
1:2
a,b 
3:1 
 6a 
 
16 Cis ~60  3:1 
 6b 
 
16 Trans ~10  3:1 
 7a 
 
18 Cis >100  3:1 
 7b 
 
18 Trans ~27 3:1 
a
(Dutta, 2010a). N.A.- Not Applicable, because there is only one stereo center at 
phosphate, therefore, there are no diastereomers. N.D.- Not Determined. 
b
Some IC50s 
were sensitive to PC:PI ratios. 
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potent cyclipostin derivative was cyclipostin P Trans (3b) with an IC50 of 25±15 nM 
against HSL. This indicated that the long carbon tail on the phosphate moiety is critical 
for successful inactivation of rat HSL (Fig. 6.2). 
6.3.1.2 Phosphate vs. Phosphonate Moiety in Cyclipostin Derivatives:   
According to the proposed mechanism, the active site serine of HSL attacks the 
phosphate in cyclipostin derivatives. Therefore, the reactivity of the phosphate was 
examined. If the phosphorus atom is surrounded only with oxygen atoms, there is less 
electron density around the phosphorus than when the phosphorus atom is bound to one 
carbon atom (oxygen to carbon substitution). This electron density shift had an influence 
on inhibitor potency. Cyclipostin derivatives with a phosphate moiety (2a,b; 3a,b, 10) 
were more potent than cyclipostin derivatives with a phosphonate moiety (4a,b; 5a,b, 25) 
(Table 6.5, Fig. 6.2). Following this example that an inhibitor was more potent whenever 
the electrophile was surrounded by electron withdrawing atoms, compound 9 was 
synthesized with strong electron withdrawing fluorine atoms. The inhibitory effect of this 
compound was expected to exceed the inhibitory effect of the cyclipostin P Trans (3b), 
but for unknown reasons, the compound with two fluorides did not succeed in inhibiting 
rat HSL even at 100 μM. It was theorized that there was an electrostatic clash between 
the fluorine atoms and the HSL active site. 
6.3.1.3 Bicyclic vs. Monocyclic Cyclipostin Derivatives: 
The next issue that was addressed was the effect of the presence of the lactone 
ring in phosphate-containing cyclipostin derivatives.  Bicyclic (3a,b) or monocyclic (10) 
phosphate cyclipostin derivatives with the phosphate moiety showed the same level of 
HSL inhibition in low nM range. Bicyclic (5a,b) and monocyclic (25) phosphonate  
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Figure 6.2: (A) The Effect of the Alkyl Tail on the Inhibitory Effect of the 
Cyclipostin Derivatives. Addition of the long alkyl tail increased inhibitory effect of the 
cyclipostin compound 4000 fold against rat HSL. (B) Inhibitory Effect of Cyclipostin P 
and R with Phosphate or Phosphonate Moiety. Presence of the phosphonate moiety 
drastically decreased the inhibitory effect of the compounds against rat HSL. 
 
 
 
 
 
 
 
 
A B 
B 
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cyclipostin derivatives showed the same level of HSL inhibition (nM range) in  
comparison with one another. Therefore, the lactone ring did not play a role in the 
inhibitory effect of cyclipostin derivatives on HSL (Fig. 6.3).      
6.3.1.4 Position of the Alkyl Tail; the Length of the Tail: 
The dependence of the inhibitory effect of cyclipostin derivatives with a 
phosphonate moiety on the alkyl tail position with respect to its length was addressed. If a 
16 carbon tail was placed on the phosphate moiety of the cyclipostin derivative (25), it 
showed 19 to 100-fold increase in inhibition compared to the cyclipostin derivative with 
a 16 carbon tail placed at the 5 position in a phosphate-containing, seven-membered ring 
(6a,b) (Fig. 6.4). The potency of the inhibitor increased as the length of the C-chain 
increased but with exceptions due to stereo selectivity (Fig. 6.4). Compounds 22a and 
22b, 23a and 23b, 24a and 24b, 6a and 6b, 7a and 7b have tails that are 5, 10, 12, 16, 18 
carbons long at the 5 position, respectively (Table 6.5). Compounds with 16 carbon tails 
were the most potent.  
6.3.1.5 HSL Stereoselectivity: 
Cyclipostin derivatives have two stereo centers: the phosphate moiety and the 
carbon between the seven-membered ring and the lactone ring (carbon chain). The 
inhibitory effect of cyclipostin derivatives with the phosphate moiety (2a,b; 3a,b) 
depended on the diastereomer. Cis cyclipostin R (C15) was a more potent inhibitor than 
Trans cyclipostin R, while Trans cyclipostin P (C16) was a more potent inhibitor than Cis 
cyclipostin P. A conclusion on stereospecificity of HSL could not be drawn for these 
compounds.    
Three out of five cyclipostin derivatives with a phosphonate moiety (22a,b;23a,b;  
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Figure 6.3: Summary of SAR Studies with Cyclipostin Derivatives (Bicyclic 
Phosphates) against HSL. The presence of a C16 tail increased the IC50 of the 
cyclipostin derivative with C15 tail ~4000 fold over the cyclipostin derivative with a C1 
tail. The presence of the phosphate moiety increased the inhibitory effect of the 
cyclipostin derivative with C16 tail ~ 280 fold over the cyclipostin derivative with a 
phosphonate moiety. The presence or absence of the lactone ring in cyclipostin 
derivatives with a phosphate moiety and C16 did not exhibit any change in inhibitory 
effect. 
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Figure 6.4: (A) The Effect of the Phosphate to Phosphonate Substitution on the 
Inhibitory Effect of the Cyclipostin Derivatives. Position of the alkyl tail in the 
cyclipostin molecule changed inhibitory effect of the molecule up to 100-fold. Compound 
(10) and (6 a,b) have the same C16 alkyl tail but on a different position in the molecule. 
Compound (10) has the tail off the phosphate moiety, while compound 6 has it off 
position 5 of the seven-membered ring. (B) Dependence of the Inhibitory Effect on the 
Alkyl Chain Length. The inhibitory effect of the cyclipostin derivatives against rat HSL 
increased as the length of the alkyl chain increased.  
  
 
 
 
 
 
 
A B 
10 6 5 
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24a,b; 6a,b; 7a,b) showed a better inhibitory effect in the Trans diastereomer than in the 
Cis (23ab, 6ab, 7ab) (Table 6.3). One of the phosphonate containing cyclipostin 
derivatives exhibited better inhibitory effect in the Cis diastereomer (24a,b), and one of 
the phosphonate containing compounds had no stereo selectivity (22a,b) (Fig. 6.5). 
According to the studies performed by the Jean−Francois Cavalier group, one of 
the lipases that belongs to the HSL family had preference for the Cis diastereomer of the 
above compounds (Table 6.6) (Point et al., 2012).  The same preference was seen against 
a monoglyceride lipase and a fungal lipase. It was interesting to note that the monocyclic 
cyclipostin derivative with an alkyl chain at the 5
th
 position with C12 (24a,b) had better 
inhibition against monoglycerol lipase (Rv0183) in the Trans diastereomer, while the rest 
of the compounds (22a,b;23a,b; 6a,b; 7a,b) were more potent in the Cis diastereomer 
(Table 6.6). In comparison with the studies performed by the Dupureur group on HSL, 
diastereomer preference was for the Trans diastereomer, while in the group of Dr. 
Cavalier enzymes Rv0183 (MGL family) and LipY (HSL family) the preference was for 
the Cis diastereomer.   
Therefore, presence of an alkyl tail and a phosphate moiety were necessary to 
exhibit a good inhibitory effect towards HSL. The lactone ring did not affect the 
inhibitory effect of the cyclipostin derivatives. From all the data gathered, there was no 
conclusion about stereo selectivity or tail length of cyclipostin derivatives inhibitory 
ability towards HSL. 
6.3.2. Kinetic Analysis of Cyclipostin P with Rat HSL: 
The most potent cyclipostin studied (P Trans) was subjected to a more detailed 
kinetic analysis.  
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Figure 6.5: The Inhibitory Effect of the Monocyclic Phosphonate Cyclipostin 
Derivatives on Rat HSL.  
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Table 6.6: Inhibitory Effect of Organophosphonates of Different Lipases. 
Compound Structure Tail  Diastereomer Rv0183
a
  
(MGL 
gene 
family) 
LipY
a
  
(HSL 
gene 
family) 
Rat 
HSL 
 
22b 
  
5 
Cis 2
 >170 10
b 
 
22a 
  
Trans 3
 
>170 10
b 
 
23b 
  
10 
Cis 1
c 
5 30
b 
 
23a 
  
Trans 3 43 10
b 
 
24b 
  
12 
Cis 5 6 5
b 
 
24a 
  
Trans 2 10 18
b 
 6a 
 16 
Cis 2 1
d 6 
 6b 
 
Trans >90 6 1
e 
 7a 
 18 
Cis 3 1
d
 10 
 7b 
 
Trans >90 12 3 
a
(Point et al., 2012); 
b
(Dutta, 2010a). 
c
All inhibitory potencies for Rv0183 were 
calculated relative to the 23b (smallest value). 
d
All inhibitory potencies for LipY were 
calculated relative to the 6a and 7a (smallest value). 
e
All inhibitory potencies for HSL 
were calculated relative to the 6b (smallest value). Bolded values mean steric preference 
of the enzyme for inhibitor.  
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This was performed as described in Materials and Methods (Chapter 5.3.5). The  
residual activity of the enzyme was determined as the 100 – activity of the enzyme at 
each concentration of cyclipostin P Trans. Eqn.1 (At = A0 [(1-k-2 / kobs) * e^ (-kobs t) + k-2 / 
kobs]) was fitted to the residual activity of the enzyme with respect to the reaction time 
(I+E+S) to obtain the reverse inactivation rate constant (k-2) (Fig. 6.6). k-2 for this 
inhibitor concentration as well as for every other concentration of cyclipostin P Trans 
was close to zero, therefore the cyclipostin P Trans was an irreversible inhibitor. 
The next step in analysis was to determine the forward inactivation rate constant 
(k2) and inhibition equilibrium constant (KI) parameters. To achieve that, the difference 
of the counts per minute (CPM) in the beginning and end of the reaction was obtained for 
each concentration of cyclipostin P Trans. Then ΔCPM for each concentration of 
inhibitor was normalized to 1 (0 nM cyclipostin P Trans), and plotted with respect to the 
concentration of cyclipostin P Trans. This plot was fitted to eqn. 2 (kobs = k2 * [I] / 
(KI+[I])) (Fig. 6.7). The average of k2 from four experiments was 0.9 min
-1
, and the 
average of the KI was 32.3 nM. From the previously studied member of the cyclipostin 
family (cyclophostin) against human acetylcholinesterase (hydrolase family), the forward 
inactivation rate constant (k2) was between 0.3- 4.2 min
-1
 while well known hydrolase 
inhibitor DIFP (diisopropylfluorophosphate) had a k2 of 1.0 min
-1
 (Dutta et al., 2010b). 
Therefore, the k2 obtained for cyclipostin P Trans fell into the right range of the forward 
inactivation rates for similar compounds. The KI for the cyclipostin P Trans was 32.2 nM 
while the IC50 for this compound is 25±15 nM; therefore, the inactivation equilibrium 
constant fell into the range of IC50. 
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Figure 6.6: Kinetic Analysis: Determination of Reverse Inactivation Rate Constant. 
(Left) The enzyme activity during reaction of 20 nM cyclipostin P Trans with 80 nM rat 
HSL. The activity was normalized to 100 %. (Right) The normalized activity of enzyme 
was inverted to get % residual activity and fitted to Eqn. 1: At = A0 [(1-k-2 / kobs) * e^ (-
kobs t) + k-2 / kobs] to get the parameter k-2. k-2 was close to zero; therefore, the cyclipostin 
P Trans is an irreversible inhibitor. The inhibitor was added to the enzyme at the same 
time as enzyme substrate.                    
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Figure 6.7: Determination of Forward Inactivation Rate Constant (k2) and 
Inhibition Equilibrium Constant (KI) (4 Different Experiments). Difference of the 
counts per minute (CPM) in the beginning and end of the reaction was obtained for each 
concentration of cyclipostin P Trans. Then ΔCPM for each concentration of inhibitor was 
normalized to 1 (0 nM cyclipostin P Trans), and plotted with respect to the concentration 
of cyclipostin P Trans. The plot never reached zero because the difference between the 
counts in the beginning and the end of the reaction never reached zero. This plot was 
fitted to eqn. 2 (kobs = k2 * [I] / (KI+[I])). The average of the k2s from four experiments 
was 0.93 min
-1
, and the average of KI was 32.3 nM. The inhibitor was added to the 
enzyme at the same time as enzyme substrate.        
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In conclusion, cyclipostin P Trans is an irreversible inhibitor of the rat HSL with 
an inactivation equilibrium constant (KI) close to the IC50 for this compound and 
inactivation rate of 0.9 min
-1
 which was close to the AChE inactivation rates.                        
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